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Abstract         
        This study was carried out on ninety six egg samples collected from laying hens 
from commercial chicken farm at Alhalfaia (Khartoum North). The hens were 
vaccinated against Newcastle disease (ND) with the Newcastle disease virus (NDV) 
vaccine (Komorov strain) produced in the Central Veterinary Research Laboratories 
center (Khartoum, Sudan).This experiment attempt to detect the presence of 
immunoglobulin Y (IgY) in the egg yolk as a result of transfer of maternal 
antibodies from  immunized hen’s sera to the egg yolk and to study the specificity of 
these antibodies to NDV.The immunoglobulin Y(IgY) was extracted from egg yolk 
by dextran sulphate method. The method of extraction consists of three steps: 
Precipitation of lipids by dextran sulphate; precipitation of proteins by sodium 
sulphate; and dialysis of precipitate against tris- buffered saline (TBS).  
        The presence of IgY in egg yolk, antibody titers and specificity to Newcastle 
disease virus (NDV) were determined by standardized indirect ELISA (In- house 
ELISA). All Ninety six samples were found positive (100%). The positive results 
were varied in titers between log2 13.643 (the maximum) and log2 8.643 (the 
minimum). As comparative study, detection of maternal specific NDV IgY was 
done using NDV antibody test kit. All samples tested were found positive and 
antibody titers were varied between log2 14.171 (the maximum) and log2 10.838 (the 
minimum). It was found that titers obtained from NDV antibody test kit were higher 
than those obtained from the standardized indirect ELISA. From this study, it was 
found that maternally derived IgY antibodies present in the egg yolk specific to 
NDV were present in high titers that confer protection during early weeks of life of 
newly hatched chicks. Extraction of maternally derived specific NDV antibodies 
from yolk will facilitate accurate monitoring of ND vaccination programmes.   
 
 
 
 
 
IV 
 ﻣﻠﺨﺺ اﻷﻃﺮوﺣﻪ
 
اﺟﺮﻳﺖ هﺬﻩ اﻟﺪراﺳﻪ ﻋﻠﻰ ﺳﺖ و ﺗﺴﻌﻮن ﻋﻴﻨﺔ ﺑﻴﺾ ﺟﻤﻌﺖ ﻣﻦ دﺟﺎج ﺑﻴﺎض ﻣﻦ اﺣﺪى 
هﺬا اﻟﺪﺟﺎج ﺗﻢ ﺗﻄﻌﻴﻤﻪ ﺿﺪ . ﻣﺰارع اﻟﺪواﺟﻦ اﻟﺘﺠﺎرﻳﻪ ﺑﻤﻨﻄﻘﺔ اﻟﺤﻠﻔﺎﻳﺎ ﺷﻤﺎل اﻟﺨﺮﻃﻮم
ﻋﺘﺮة اﻟﻜﻤﻮروف اﻟﻤﻨﺘﺞ ﻓﻲ ، ﺑﻠﻘﺎح ﻣﺮض اﻟﻨﻴﻮآﺎﺳﻞ( ﻣﺮض ﺳﻤﻴﺮ)ﻣﺮض اﻟﻨﻴﻮآﺎﺳﻞ 
هﺬﻩ اﻟﺘﺠﺮﺑﻪ هﻲ ﻣﺤﺎوﻟﻪ (. اﻟﺴﻮدان، ﺨﺮﻃﻮماﻟ)ﻣﺮآﺰاﻟﻤﻌﺎﻣﻞ واﻟﺒﺤﻮث اﻟﺒﻴﻄﺮﻳﻪ اﻟﻤﺮآﺰﻳﺔ 
ﻓﻲ ﻣﺢ اﻟﺒﻴﺾ واﻟﻤﻮﺟﻮدﻩ آﻨﺘﻴﺠﻪ ﻻﻧﺘﻘﺎل  YgIﻟﻠﻜﺸﻒ ﻋﻦ وﺟﻮد اﻻﺟﺴﺎم اﻟﻤﻀﺎدﻩ ﻧﻮع 
اﻟﻤﻨﺎﻋﻪ اﻻﻣﻴﻪ ﻣﻦ ﻣﺼﻞ اﻻﻣﺎت اﻟﻤﻤﻨﻌﻪ اﻟﻰ ﻣﺢ اﻟﺒﻴﺾ وﻣﻦ ﺛﻢ دراﺳﺔ ﺧﺼﻮﺻﻴﺔ هﺬﻩ 
ﻣﻦ   YgI ﺗﻢ اﺳﺘﺨﻼص اﻻﺟﺴﺎم اﻟﻤﻀﺎدﻩ. اﻻﺟﺴﺎم اﻟﻤﻀﺎدﻩ ﻟﻔﻴﺮوس ﻣﺮض اﻟﻨﻴﻮآﺎﺳﻞ
ﺗﺮﺳﻴﺐ : ﺗﺘﻜﻮن هﺬﻩ اﻟﻄﺮﻳﻘﻪ ﻣﻦ ﺛﻼث ﻣﺮاﺣﻞ.  ﻣﺢ اﻟﺒﻴﺾ ﺑﻄﺮﻳﻘﺔ آﺒﺮﻳﺘﺎت اﻟﺪآﺴﺘﺮان
ﺗﺮﺳﻴﺐ اﻟﺒﺮوﺗﻴﻦ ﺑﻮاﺳﻄﺔ آﺒﺮﻳﺘﺎت اﻟﺼﻮدﻳﻮم ﺛﻢ ، اﻟﺪهﻮن ﺑﻮاﺳﻄﺔ آﺒﺮﻳﺘﺎت اﻟﺪآﺴﺘﺮان
ﻣﻌﻴﺎرهﺎ وﺧﺼﻮﺻﻴﺘﻬﺎ ﻟﻔﻴﺮوس ﻣﺮض ، YgI ﺣﺪد وﺟﻮد اﻻﺟﺴﺎم اﻟﻤﻀﺎدﻩ. اﻟﺪﻳﻠﺰة
وﺟﺪت ﺟﻤﻴﻊ اﻟﻌﻴﻨﺎت ﻣﻮﺟﺒﺔ . ﺎﺷﺮﻩ اﻟﻤﺤﻀﺮﻩ ﺑﺎﻟﻤﻌﻤﻞاﻟﻨﻴﻮآﺎﺳﻞ ﺑﻮاﺳﻄﺔ اﻻﻟﻴﺰا ﻏﻴﺮ اﻟﻤﺒ
ﺗﺮاوح ﻣﻌﻴﺎر اﻻﺟﺴﺎم اﻟﻤﻀﺎدﻩ ﻓﻲ (. 001)%ﻟﻮﺟﻮد اﻻﺟﺴﺎم اﻟﻤﻀﺎدﻩ ﻓﻲ ﻣﺢ اﻟﺒﻴﺾ
ﻟﻠﻤﻘﺎرﻧﺔ ﺗﻢ اﻟﻜﺸﻒ ﻋﻦ  .346.8واﻗﻞ ﻣﻌﻴﺎر 346.31اﻟﻌﻴﻨﺎت اﻟﻤﻮﺟﺒﺔ ﺑﻴﻦ اﻋﻠﻰ ﻣﻌﻴﺎر
وﺟﺪت ﺟﻤﻴﻊ  .وﺟﻮد اﻻﺟﺴﺎم اﻟﻤﻀﺎدﻩ ﻟﻔﻴﺮوس ﻣﺮض اﻟﻨﻴﻮآﺎﺳﻞ ﺑﺎﺳﺘﻌﻤﺎل ﻃﻘﻢ اﻻﻟﻴﺰا
ﻣﻌﻴﺎر اﻻﺟﺴﺎم  ﺗﺮاوح(. 001)%اﻟﻌﻴﻨﺎت ﻣﻮﺟﺒﺔ ﻟﻮﺟﻮد اﻻﺟﺴﺎم اﻟﻤﻀﺎدﻩ ﻓﻲ ﻣﺢ اﻟﺒﻴﺾ 
آﻤﺎ وﺟﺪ أن  838.01وأﻗﻞ ﻣﻌﻴﺎر 171.41اﻟﻤﻀﺎدﻩ ﻓﻲ اﻟﻌﻴﻨﺎت اﻟﻤﻮﺟﺒﺔ ﺑﻴﻦ اﻋﻠﻰ ﻣﻌﻴﺎر 
ﻣﻌﻴﺎر اﻻﺟﺴﺎم اﻟﻤﻀﺎدﻩ اﻟﻤﺘﺤﺼﻞ ﻋﻠﻴﻪ ﻣﻦ هﺬﻩ اﻟﺘﺠﺮﺑﻪ أﻋﻠﻰ ﻣﻦ ذﻟﻚ اﻟﻤﺘﺤﺼﻞ ﻋﻠﻴﻪ ﻣﻦ 
 . ﻏﻴﺮ اﻟﻤﺒﺎﺷﺮة اﻟﻤﺤﻀﺮﻩ ﺑﺎﻟﻤﻌﻤﻞﺗﺠﺮﺑﺔ اﻹﻟﻴﺰا 
ﻣﻦ هﺬﻩ اﻟﺪراﺳﺔ وﺟﺪ ان اﻻﺟﺴﺎم اﻟﻤﻀﺎدﻩ اﻟﻤﻨﺤﺪرﻩ ﻣﻦ اﺻﻞ اﻣﻲ واﻟﻤﻮﺟﻮدﻩ ﻓﻲ ﻣﺢ 
اﻟﺒﻴﺾ ﻟﻬﺎ ﺧﺼﻮﺻﻴﻪ ﻟﻔﻴﺮوس ﻣﺮض اﻟﻨﻴﻮآﺎﺳﻞ وﺗﺘﻮاﺟﺪ ﺑﻤﻌﺎﻳﻴﺮﻋﺎﻟﻴﺔ ﺗﻤﻨﺢ اﻟﻮﻗﺎﻳﺔ 
اﺳﺘﺨﻼص اﻷﺟﺴﺎم . ﻟﻠﻜﺘﺎآﻴﺖ ﺿﺪ ﻣﺮض اﻟﻨﻴﻮآﺎﺳﻞ ﺧﻼل اﻷﺳﺎﺑﻴﻊ اﻷوﻟﻰ ﺑﻌﺪ اﻟﻔﻘﺲ
دﻩ ﻟﻔﻴﺮوس ﻣﺮض اﻟﻨﻴﻮآﺎﺳﻞ واﻟﻤﻨﺤﺪرﻩ ﻣﻦ اﺻﻞ اﻣﻲ ﻣﻦ ﻣﺢ اﻟﺒﻴﺾ ﻳﺴﺎﻋﺪ ﻓﻲ اﻟﻤﻀﺎ
                                                                                    .ﺗﻘﻴﻴﻢ ﺑﺮاﻣﺞ اﻟﺘﻠﻘﻴﺢ ﺿﺪ ﻣﺮض اﻟﻨﻴﻮآﺎﺳﻞ
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 1
INTRODUCTION 
 
        Very young chicks are susceptible to many pathogens during the first few 
weeks of age because their immune system is not fully developed (Hamal et 
al., 2006). An evolutionary attempt to compensate for the immaturity is 
expressed in a maternal immunity component consisting of antibody absorbed 
from the egg and provided by the dam in a proportionate manner (Ask et al., 
2004). Hence, maternal antibodies are the primary means of antigen-specific 
protection (Hamal et al., 2006).  
        Chickens are susceptible to many infectious diseases. One of the most 
important of these is the viral disease known as Newcastle disease, which 
causes devastating losses in both commercial and village chickens (Grimes, 
2002). ND is caused by avian paramyxovirus serotype one (APMV–1) viruses 
(Aldous and Alexander, 2001). This disease can be controlled by the use of 
vaccines and there are many Newcastle disease vaccines suitable for use in 
chickens (Grimes, 2002). Because of the severe nature of the disease and the 
associated consequences, ND is included as an Office Internationale des 
Epizooties (OIE) list a disease (Office Internationale des Epizooties, 2001). 
Nevertheless, ND is enzootic in some areas of the world and remains a 
constant threat to most birds (Aldous and Alexander, 2001). Chickens that 
survive infection with virulent Newcastle disease virus develop a long lasting 
immunity to further infection with Newcastle disease virus. The basis of this 
immunity is circulating antibodies, secretory antibody (producing mucosal 
immunity) and cell mediated immunity (Grimes, 2002).   Hens with antibodies 
to NDV will pass these on to their progeny via the egg yolk. The populations 
of IgY are transported according to their concentration in the maternal serum 
(Carlander, 2002) and thus levels of antibody in day- old chicks will be 
directly related to titers in the parent (Alexander, 2003). Maternal antibodies 
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protect chicks for three to four weeks after hatching (Murphy et al., 1999). 
There is no doubt that maternal antibody can influence the response to 
vaccination during the first weeks of life (McMullin, 1985).  
         Seromonitoring of humoral immune response in vaccinated chicken 
flocks is necessary for controlling Newcastle disease. In regular antibody 
detection, bleeding of animal is necessary to purify antibodies from the blood 
serum. Bleeding of chickens is considered painful and usually causes large 
haematoma because chickens have fragile veins. Chicken egg yolk IgY offers 
an easy and acceptable alternative for production of antiserum. 
Several methods can be used for the extraction of IgY from egg yolk, 
and commercial extraction kits are available (Schade et al., 1996). The choice 
of method is a matter of yield and purity desired, final use of the IgY as well 
as material cost and labor skills (Carlander, 2002). A number of methods have 
been published for the detection of antibodies against Newcastle disease virus 
(NDV) by means of enzyme-linked immunosorbent assays (ELISAs) and 
commercial kits have also been produced (Bell, et al., 1991).  
The main aims of the present study were i) to extract IgY antibodies 
from egg yolk ii) to elaborate in-house ELISA for measurement of specific 
maternally derived NDV antibodies and  iii) to test the specificity of egg yolk 
antibodies to Newcastle disease virus.  
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CHAPTER ONE 
LITERATURE REVIEW 
1.1 Definition 
Newcastle disease (ND) is a deadly viral disease of poultry causing high 
mortality due to its high contagiousness and rapid spreading among chicken 
and other domestic and semi-domestic species of birds (Rahman et al., 2002 
and Murphy et al., 1999). The virus has a wide host range, most orders of 
birds reported to have been infected by Newcastle disease virus (NDV) (Seal 
et al., 2000). It is enzootic (endemic) in most countries in Africa, Asia and 
South America, where it continues to cause serious losses despite the 
vaccination of industrialized poultry (Tabidi et al., 2004).  
        The ‘OIE’ defined ND as “a disease of birds caused by strains of Avian 
PMV-1, significantly more virulent than lentogenic strain...” whereas the 
European Council Directives defined ND as “an infection of poultry caused by 
Avian PMV-1 in day-old chicks with ICPI greater than >0.7.”(Survashe and 
Desmukh, 1998).  
1.2 Disease history  
Newcastle disease has been one of the most important diseases of 
poultry worldwide. The disease was first observed in Java in 1926 (Murphy et 
al., 1999 and Seal et al., 2000), and in the same year it spread to England, 
where it was first recognized in Newcastle, hence the name Newcastle disease. 
(Murphy et al., 1999 and Alexander, 1988). The agent of ND was recovered 
in 1926 by Doyle from diseased birds (Hofsade et al., 1978).   
1.3 Classification of Newcastle disease virus (NDV) 
Newcastle disease virus is a member of the Paramyxoviridae family 
(Seal et al., 2000) in the order Mononegavirales. This virus family is divided 
into two subfamilies, the Paramyxovirinae and the Pneumovirinae. The 
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subfamily Paramyxovirinae has three genera: Rubulavirus, Respirovirus and 
Morbillivirus (Alexander, 2003). In 1993 the International Committee on 
Taxonomy of Viruses rearranged the order of the Paramyxovirus genus and 
placed NDV within the Rubulavirus genus among the Paramyxovirinae (Seal 
et al., 2000).   
         Nine serogroups of avian paramyxoviruses have been recognized, 
APMV-1 to APMV-9 (Alexander, 2003).  ND is caused by avian 
paramyxovirus serotype 1 (APMV–1) viruses. Recent work involving the 
sequencing of the whole NDV genome has suggested that avian 
paramyxoviruses are sufficiently different from other rubulaviruses to warrant 
placing them in a separate genus (Aldous and Alexander, 2001).  
1.4 Virus structure 
1.4.1 The virion  
        Paramyxovirus  virion  is  pleomorphic  in  shape  (spherical  and      
filamentous forms occur), 150-300nm in diameter. A virion is enveloped, 
covered with large peplomers (8-20 nm in length), and contain "herringbone-
shape" helically symmetrical nucleocapsid, 600-800 nm in length and 18 nm 
in diameter. The spikes (peplomers) shown in Figure (1) are composed of two 
glycoproteins: a haemagglutinin- neuraminidase (HN) protein and fusion (F) 
protein, which are the antigenic components that stimulate the host to produce 
haemagglutinin - inhibiting and virus – neutralizing antibodies (Hofsade et al., 
1978 and Murphy et al., 1999) 
1.4.2 Newcastle disease virus genome 
        The virus genome consists of a single linear molecule of negative- sense, 
single- stranded RNA, approximately 15-16 kb in size (Murphy et al., 1999), 
which codes for six proteins including RNA directed RNA polymerase (L), 
haemagglutinin- neuraminidase (HN) protein, fusion (F) protein, matrix (M) 
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protein, phospho-protein (P) and nucleoprotein (NP) as shown in Figure (2). 
Transcription occurs in the 3' to 5' direction (Seal et al., 2000). The HN 
glycoprotein is responsible for virus attachment to the cell surface receptors. 
The F glycoprotein is responsible for fusion between the cellular and viral 
membranes and subsequent virus genome penetration (Aldous and Alexander, 
2001). 
1.5 Virus replication  
        Intracellular virus replication takes place within cytoplasm.  Because the  
virus RNA has negative sense, the viral RNA-directed RNA- polymerase 
(transcriptase) must produce complementary transcripts of positive sense that 
may act as messenger RNA and use the cell’s mechanisms, enabling the 
translation into proteins and virus genomes. The F protein is synthesized as a 
non functional precursor, F0 that requires cleavage to F1 and F2 by host 
proteases. This cleavage has significance in the pathogenicity of NDV strains. 
The HN of some strains of NDV also requires posttranslational cleavage 
(Alexander, 2003).   
1.6 Virus properties   
1.6.1 Physico-chemical properties  
The infectivity of NDV and other avian paramyxoviruses may be 
destroyed by physical and chemical treatments such as heat, irradiation 
(including light and ultra violet rays), oxidation processes, pH effects, and 
various chemical compounds. The rate at which infectivity is destroyed 
depends on the strain of the virus, the length of exposure, the nature of the 
suspending medium, and interactions between treatments. No single treatment 
can guarantee destruction of all viruses but may result in a low probability of 
remaining infective virus (Alexander, 2003).   
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Fig. 1: Newcastle disease virus structure.  
Newcastle disease virus (NDV) is an enveloped virus with two surface 
glycoproteins, the fusion (F) and attachment haemagglutinin-neuraminidase 
(HN) proteins. The matrix (M) protein is juxtaposed between the envelope and 
the interior nucleocapsid structure. The nucleoprotein (NP), phosphoprotein 
(P) and polymerase (L) proteins make up the transcriptase complex and are in 
close contact with the viral genome (Seal et al., 2000).  
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Fig. 2: Newcastle disease virus genomic organization.  
NDV genome is a single-strand,negative sense RNA encoding six open 
reading frames. The P protein gene is polycistronic due to insertion of at least 
one additional guanosine during transcription and utilization of potential 
alternative transcription start sites (Seal et al., 2000).  
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1.6.2 Biological properties   
1.6.2.1 Haemagglutination  
All strains of Newcastle disease virus agglutinate chicken red blood 
cells. The linking together of the red blood cells by the viral particles results in 
clumping. This clumping is known as haemagglutination. Haemagglutination 
is visible macroscopically and is the basis of haemagglutination tests to detect 
the presence of viral particles (Grimes, 2002).  
        The process of haemagglutination consists of the attachment of the virus 
to the receptor substance on the cell (erythrocyte) surface causing clumping of 
the cells (agglutination) followed later by the destruction of the receptor 
substance by the enzyme neuraminidase. This second step is associated with 
the release (elution) of the virus from the surface of the cell (Hofsade et al., 
1978).  
        Antibody response to the haemagglutinin protein in the Newcastle 
disease virus envelope can be measured by the Haemagglutination inhibition 
(HI) test. When serum containing these antibodies is mixed with Newcastle 
disease virus, the antibodies bind to the haemagglutinin protein in the 
envelope of the virus. This blocks the haemagglutinin protein from binding 
with the receptor site on chicken red blood cells. Thus the haemagglutination 
reaction between the virus and the red blood cells is inhibited (Grimes, 2002). 
Haemagglutination inhibition (HI) test is the most widely used for 
measurement of antibodies (Abs) against Newcastle disease virus (NDV) 
(Tabidi et al., 2004).  
 
1.6.2.2 Haemolysis  
NDV possesses a haemolysin. The virus is capable of lysing those 
erythrocytes that it can agglutinate (Hofsade et al., 1978). 
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1.7 Epidemiology  
        Over 250 species of birds have been reported to be susceptible to NDV as 
a result of natural or experimental infections, and it is likely that many more 
susceptible species exist but have not yet been identified (Alexander, 1997).   
1.7.1 The virus-host interaction 
Newcastle disease virus reacts with avian hosts in various ways. When 
non-immune domestic chickens encounter highly pathogenic strains of 
Newcastle disease virus, the common sequel is an acute disease with mortality 
close to 100%. The birds will often be paralyzed or have twisted necks. This 
severe disease, attributed to velogenic strains of Newcastle disease virus, 
occurs in both village and commercial poultry.  In commercial chickens, 
strains of Newcastle disease virus of moderate virulence (mesogenic strains) 
cause lower rates of mortality in mature chickens, but severely deplete egg 
production. Strains of low virulence (lentogenic strains) cause little mortality 
except in young birds, but do reduce egg production. These strains also 
interact synergistically with other pathogens, especially respiratory pathogens, 
to produce severe clinical disease (Spradbrow, 1990).  
1.7.2Transmission 
Transmission occurs by direct contact between birds by the airborne 
route via aerosols and dust particles and via contaminated feed and water. 
With lentogenic strains, transovarial transmission is important and virus-
infected chicks may hatch from virus-containing eggs. Trade in infected avian 
species and products plays a key role in the spread of Newcastle disease from 
infected to noninfected areas. Virus may also be disseminated by frozen 
chickens, foodstuff, bedding, manure, and transport containers. In birds that 
survive, the virus is shed in all secretions and excretions for at least four 
weeks (Murphy et al., 1999). 
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1.8 Pathogenicity 
The molecular basis for NDV pathogenicity is dependent on the F 
protein cleavage site amino acid sequence and the ability of specific cellular 
proteases to cleave the F protein of different pathotypes (Seal et al., 2000). 
Strains of Newcastle disease virus differ widely in virulence, depending on the 
cleavability and activation of their hemagglutinin and fusion glycoprotein 
(Murphy et al., 1999). The term velogenic (viscerotropic), mesogenic, and 
lentogenic are applied to Newcastle disease virus strains of high, intermediate, 
and low virulence respectively (Murphy et al., 1999 and Seal et al., 2000). 
Avirulent strains of Newcastle disease virus causes no disease (Grimes, 2002). 
Whereas velogenic strains kill virtually 100% of infected fowl, naturally 
avirulent strains have even been used as vaccines (Murphy et al., 1999).   
        Initially the virus replicates in the mucosal epithelium of the upper 
respiratory and intestinal tracts; shortly after infection, virus spreads via the 
blood to the spleen and bone marrow, producing a secondary viremia. This 
leads to infection of other target organs: lung, intestine, and central nervous 
system (Murphy et al., 1999).  
1.8.1Clinical features  
        In chickens, respirator, circulator, gastrointestinal, and nervous signs are  
seen; the particular set of clinical manifestations depends on the age and 
immune status of the host and on the virulence and tropism of the infecting 
strain (Murphy et al., 1999). The incubation period of ND after natural 
exposure has been reported to vary from 2-12 days and an average five to six 
days (Alexander, 2003).    
        A combination of inspiratory dyspnea (gasping), cyanosis of comb and 
wattles, and clonic muscular spasm is indicative. There is a loss of appetite, 
listlessness; Intestinal symptoms may include crop dilatation, presence of 
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foamy mucus fibrinous exudate in the pharynx, a similar discharge from the 
beak, and yellow-green diarrhea. Nervous system involvement is indicated by 
paralysis of wings and/or legs, torticollis, ataxia or circular movements, 
bobbing-and-weaving movements of the head, and clonic spasms. In layers 
there is a sudden decrease in egg production together with depigmentation 
and/or loss of shell and reduction in the albumen quality of eggs (Murphy      
et al., 1999).  
1.8.2Pathology 
Gross pathologic findings include ecchymotic haemorrhages in the 
larynx, trachea, esophagus, and throughout the intestine. The most prominent 
histologic lesions are necrotic foci in the intestinal mucosa and the lymphatic 
tissue and hyperemic changes in most organs, including the brain (Murphy et 
al., 1999).  
1.8.3 Human disease  
Newcastle disease virus can produce a transitory conjunctivitis in 
humans; usually mild and persisting  one to two days but on occasion quite 
sever and even leading to some lasting impairment of vision. The condition 
has been seen primarily in laboratory workers and vaccination teams exposed 
to large quantities of virus. The disease has not been reported in individuals 
who rear poultry or consume poultry products (Murphy et al., 1999 and 
Hofsade et al., 1978).  
1.9 Immunity to Newcastle disease virus 
Chickens that survive infection with virulent Newcastle disease virus 
develop a long lasting immunity to further infection with Newcastle disease 
virus. The basis of this immunity is circulating antibodies, secretory antibody 
(producing mucosal immunity) and cell mediated immunity. Newcastle 
disease virus of low virulence induces similar immune responses without 
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causing severe disease. This is the basis of vaccination (Grimes, 2002).           
A summary of antiviral defence mechanisms is illustrated in Figure3.  
1.9.1 Cell-mediated immune response  
Cell-mediated immunity is the initial immune response to infection with 
NDV and may be detectable as early as two to three days after infection with 
live vaccine strains. This has been thought to explain the early protection 
against challenge that has been recorded in vaccinated birds before measurable 
antibody response is seen. The cell- mediated immune response to NDV by it 
self is not protective against challenge with virulent NDV (Alexander, 2003).  
1.9.2 Humoral immune response  
Antibody production is rapid (Murphy et al., 1999).   Antibody directed 
against either of the functional surface glycopolypeptides, the HN and the F 
polypeptides can neutralize NDVs (Alexander,2003) Haemagglutination-
inhibiting antibody can be detected within four to six days of infection and 
persists for at least two years (Murphy et al., 1999). Peak response is at about 
three to four weeks (Alexander, 2003). The level of Haemagglutination-
inhibiting antibody is a measure of immunity. IgG is confined to the 
circulation and does not prevent respiratory infection, but it does block 
viremia; locally produced IgA antibodies play an important role in protection 
in both the respiratory tract and the intestine (Murphy et al., 1999). 
1.9.2.1 Immuoglobulins in chicken  
Three immunoglobulin classes have been shown to exist in chicken, 
IgA, IgM and IgY (IgG) (Carlander, 2002). IgM appears after four to five 
days following exposure to a disease organism and then disappears by 10-12 
days. IgG (IgY) is detected after five days following exposure, peaks at three 
to three and a half weeks, and then slowly decreases. IgA appears after five 
days following exposure.             
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Fig. 3: Kinetics of host defenses in response to a typical acute virus infection. 
Natural killer (NK) cells and interferon (IFN) are detected in the blood stream 
and locally in infected tissues.Cytotoxic T cells (Tc) then become activated 
followed by the appearance of neutralizing antibodies in serum (Roitt et al., 
2001). 
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This antibody is found primarily in the mucus secretions of the eyes, gut, and 
respiratory tract and provides "local" protection to these tissues (Butcher and 
Miles, 2003).  
1.9.2.2 Chicken IgY  
         The terms IgG and IgY are commonly interchanged when speaking of 
chicken immunoglobulin. Immunoglobulin from chickens and other avian 
species bear some resemblance to mammalian IgG, but also display some 
unique structural and functional characteristics that distinguish them from IgG 
(Stone et al., 1992). General structure of IgY molecule is the same as of IgG 
with two heavy  chains (HC) with a molecular mass of 67–70 kDa each and 
two light  chains (LC) with a molecular mass of 25 kDa each. The major 
difference is the number of constant regions (C) in heavy chains: IgG has 
three C regions, while IgY has four C regions. One additional C region with 
two corresponding carbohydrate chains has a logical consequence in a greater 
molecular mass of IgY compared to IgG i.e. 180 and 150 kDa, respectively. 
Narat (2003) reported that IgY is much less flexible than IgG due to the 
absence of the hinge between C1 and C2, which is a unique mammalian 
feature (Figure 4).  
        IgY is the accepted/proper term for chicken antibodies. Chicken IgY is 
the functional equivalent to mammalian IgG. It is found in the serum of 
chickens and passed from the mother chicken to the embryo via the egg yolk, 
imparting a high concentration of chicken IgY to developing embryo. The "Y" 
in IgY comes from "yolk" and is the main antibody component in the egg yolk 
(Stone et al., 1992).         
        Chicken IgY is a systemic rather than a secretory antibody but IgY is also 
found in duodenal contents, tracheal washings and seminal plasma. It is called  
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                                              A hinge 
 
Mammalian IgG  
 
 
 
               Limited flexibility 
 
 
 Avian IgY 
 
Fig.4: Structure of mammalian IgG and avian IgY.  
The major difference is the number of constant regions (C) in heavy chains: 
IgG has three C regions, while IgY has four C regions. IgY is much less 
flexible than IgG due to the absence of the hinge between C1 and C2 (Narat, 
2003). 
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IgY rather than IgG to distinguish it from its mammalian counterpart 
(Carlander, 2002).                                                                                                                     
In chickens, it has been well established that IgG (IgY) is the antibody 
isotype that is transferred from the dam to her offspring (Hamal et al., 2006) 
and is the major antibody found in eggs (Carlander, 2002). Other classes are 
present, but only in negligible amounts (Schade et al., 1996). In eggs, IgY is 
present predominantly in the egg yolk, whereas IgA and IgM are present in the 
egg white (Hamal et al., 2006).  
1.9.2.3 Stability of chicken IgY  
IgY is very stable under normal conditions. IgY antibodies have been 
stored for over 10 years at 4°C without any significant loss in antibody 
activity. Chicken antibodies have also retained their activity after six months 
at room temperature or one month at 37 °C (Raj et al., 2004).  
IgY is a protein and as such, is sensitive to denaturation. However, IgY 
is fairly heat stable (Carlander, 2002 and Szabo et al., 1998), and most 
antibody activity remain after 15 minutes at 70°C.  Incubation of IgY at pH 
above four is well tolerated, but at pH 2 and 37°C the activity is rapidly 
decreased (Carlander, 2002).  
 1.9.3 Maternal Immunity  
        Maternal antibody transmission is defined as the transfer of antibodies by 
an immunocompetent adult, typically a female, to an immunologically naive 
neonate transplacentally or through colostrum, milk, yolk, etc. The ability of 
mothers to transmit antibodies to their offspring was documented in both 
mammals and birds over 100 years ago (Grindstaff et al., 2003). 
        In many animals immunity is not fully developed until adulthood but the 
young still need protection against various sets of pathogens. Thus, bird 
nestlings  are  highly  dependent  on  antibodies  received  from  their  mother  
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(in the eggs) during their rapid early growth period. The relationship between 
maternal immunity and the development of neonates' own immunity has been 
poorly studied (Pihlaja et al., 2006).           
        An evolutionary attempt to compensate for the immaturity is expressed in 
a maternal immunity component consisting of antibody absorbed from the egg 
and provided by the dam in a proportionate manner (Ask et al., 2004). Hens 
with antibodies to NDV will pass these on to their progeny via the egg yolk. 
Levels of antibody in day- old chicks will be directly related to titers in the 
parent (Alexander, 2003). Maternal antibodies protect chicks for three to four 
weeks after hatching (Murphy et al., 1999). The advantages of maternal 
immunity are that it provides early age protection against pathogens, and that 
it prevents unfavorable development of tolerance to pathogens. Effects are 
however controversial, as it can also hinder stimulus and activation of the 
chick’s own immune system (the innate and the acquired immunity). External 
stimulus is vital for development of this, and a critical stage eventuates when 
maternal protection fades (two to four weeks of age depending on the initial 
amount of maternal antibody in the chick) (Ask et al., 2004). Very young 
chicks are susceptible to many pathogens during the first few weeks of age 
because their immune system is not fully developed; hence, maternal 
antibodies are the primary means of antigen-specific protection. There are 
many reports in the literature regarding the transfer of pathogen-specific 
antibodies from hens to their chicks via the egg and their role in the protection 
of newly hatched chicks from the pathogens. The time at which the newly 
hatched chicks start to synthesize antibodies endogenously depends on the 
type of antibody. Lawrence et al. in 1981cited by (Hamal et al., 2006) 
reported that IgY-secreting B cells are not detectable in a chick’s plasma until 
six days post hatch.                                                                                                                   
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1.9.3.1Transport of IgY from maternal serum to the offspring 
 It was in 1893 that Klemperer first described the acquisition of passive 
immunity in birds, by demonstrating the transfer of immunity against tetanus 
toxin from the hen to the chick (Carlander, 2002 and Schade et al., 2005). In 
1901 Dziergowski (cited by Mahasin E. Abdel-Rahman , M.Sc. thesis,1980, 
Cambridge, UK)   reported the passage of diphtheria antitoxin in unchanged 
serum immunoglobulin from hens’ sera to the growing egg and then from the 
yolk to the embryo and the chick.  Jukes, Fraser and Orr in 1934 reported that 
there were comparable amounts of antitoxin in the serum and in the livetin of 
egg after the injection of antitoxin in chicken. In 1946 antibodies to Newcastle 
disease were first demonstrated by Brandly, Moses and Jungherr (cited by 
Mahasin E. Abdel-Rahman, M.Sc. thesis, 1980, Cambridge, UK). They 
showed that these antibodies could be transferred from laying hens to the yolk 
and thence to the developing embryo and embryonic tissues. Since the 1980s, 
egg yolk antibodies (IgY Abs) have found a broader application, possibly due 
to the availability of commercial secondary reagents such as IgY-purification 
kits, IgY-standards, and of labelled Abs (such as alkaline phosphatase, 
fluorescein isothiocyanate and peroxidase) specifically against IgY (Schade et 
al., 2005).   
 Female birds transmit passive immunity to offspring through the 
deposition of anti-bodies in eggs (Grindstaff et al., 2003 and Hamal et al., 
2006). The transport of IgY from the hen serum to the offspring is a two-step 
process. First IgY is transported from the serum to the egg yolk in analogy to 
the cross-placental transfer of antibodies in mammals. The second step is the 
transmission of IgY from the yolk sac to the developing embryo (Carlander, 
2002 and West et al., 2004).  
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 IgY is taken up into the egg yolk by the IgY receptors on the ovarian 
follicle from the dam’s blood. In the second step, IgY is transferred from the 
egg yolk to the offspring via the embryonic circulation (Hamal et al., 2006). 
The IgY receptors on the oocyte bind and move all populations of IgY from 
the hen serum to the egg (Carlander, 2002).   
 The concentration of IgY in the yolk is essentially constant through the 
oocyte maturation, and at maturity the yolk will contain about 10-20 mg/ml 
IgY. Looking at the egg, IgY is not present in the egg white while IgA and 
IgM are not present in the yolk. There is about 100-400 mg IgY packed in the 
egg. Labeled IgY binds specifically to yolk sac tissue from day seven up to at 
least day 18. The populations of IgY are transported according to their 
concentration in the maternal serum. There is no selection nor destruction of 
IgY during transport and the yolk IgY has the same amount of sialic acid as 
the serum IgY. The amount of IgY transported is independent of egg size 
(Carlander, 2002) and known to be proportional to the maternal serum IgY 
concentration (Hamal et al., 2006 and Carlander, 2002).    
 In the newly hatched chick the IgY concentration in circulation is about 
1-1.5 mg/ml and the circulating half-life of IgY is about 36 hours. IgY 
secreting cells in the offspring are not detectable until six days after hatching 
(Carlander, 2002).   
 Structurally, IgY is identical to the major immunoglobulin (Ig) found in 
serum (Schade et al., 1996 and Szabo et al., 1998). There is still controversy 
about the relative concentrations of the different types of Igs found in egg yolk 
and serum; the data available indicate that IgY is more highly concentrated in 
yolk than it is in serum (Schade et al., 1996 and Raj et al., 2004).  
        IgY levels, total or antigen-specific, in the dams’ plasma or eggs were 
found to be a direct indicator of maternal antibody transfer to the chicks’ 
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circulation, with an expected percentage transfer of approximately 30%. This 
knowledge, may find direct application in formulating strategies for protecting 
chicks, especially during the first few weeks of age when their immune system 
is not yet fully functional (Hamal et al., 2006).  
1.9.3.2 Maternal immunity and vaccination          
            Factors which interfere with immunization of commercial poultry can 
be divided into three main groups. They are: factors associated with the 
vaccine itself, those of vaccine administration, and those which are 
endogenous to the bird. Circulating antibody may affect the response to 
vaccination. Baby chicks at one to three days of age have circulating 
antibodies in similar concentrations to those found in dams. The titers fall to 
be undetectable by 14 - 30 days (depending on the method of detection used). 
There is no doubt that maternal antibody can influence the response to 
vaccination during the first weeks of life (McMullin, 1985). Maternal antibody 
interferers with active immunization, presumably by sequestering vaccine 
antigen or restricting replication of vaccine virus (Stone et al., 1992). Maternal 
antibody is protective and thus, taken into consideration during primary 
vaccination. It was reported that maternal antibody neutralizes the introduced 
vaccine antigen rendering the vaccine ineffective. It was mentioned that 
immune response was nil at high titer of maternal antibody (Rahman et al., 
2002).  
1.9.3.3 Simulation of maternal immunity  
        Simulation of maternal immunity by inoculation of immune yolk 
preparation in to the yolk sac of one-day-old chickens was done by Stone et 
al. (1992). In their work, yolk was harvested from eggs laid by hens 
hyperimmunized with killed Newcastle disease virus (NDV) and inoculated 
into the yolk sac of one-day-old specific-pathogen-free (SPF) chickens. Serum 
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haemagglutination-inhibition antibody titers reached maximum levels one to 
four days after yolk inoculation and declined at a rate similar to that reported 
for naturally acquired maternal antibody. Expected levels of immune 
interference were observed when yolk-inoculated chickens were vaccinated 
with a conventional oil-emulsion NDV vaccine. These results show that yolk-
sac inoculation with yolk antibody is a suitable approach for producing 
maternally immune chickens for laboratory studies. 
        In 1980, the simulation was done also by Mahasin E.  Abdel-Rahman. 
She used the whole yolk from eggs produced from hyperimmunized hens. In 
her experiment one- day old chicks hatched from non- immune hens were 
injected subcutaneously with immune yolk. The antibodies were demonstrable 
in chick’s blood two hours after injection. The immunity produced was last 
only for few weeks.  She reported that passive immunization for one-day old 
chicks is important because one-day old chicks may not respond efficiently to 
active vaccination while they can readily absorb passively injected antibodies. 
This may have its implication in areas where Newcastle disease is endemic 
and protection is needed at all times.  
1.10 Laboratory Diagnosis of NDV  
        Because clinical signs are relatively nonspecific and because the disease 
is such a threat, diagnosis must be confirmed by virus isolation and serology. 
Diagnosis can be attempted about one week after onset of the symptoms and 
repeated one week later in case of inconclusive results (Murphy et al., 1999).  
1.10.1 Virus isolation 
        The virus may be isolated from spleen, brain, or lungs by allantoic 
inoculation of 10-day-old embryonated eggs, with the virus being 
differentiated from other viruses by haemadsorption- and haemagglutnation-
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inhibition tests. Virus can be isolated from the gut when circulating antibodies 
are already present (Murphy et al., 1999).  
        Pathotype prediction initially involves NDV inoculation of embryonated 
eggs to determine mean death time of the embryo (MDT). Further testing 
entails inoculation of chickens to determine the intracerebral pathogenicity 
index (ICPI) and the intravenous pathogenicity index (IVPI) (Seal et al., 
2000). 
1.10.2 Serological tests 
        Immunofluorescence on tracheal sections or smears is rapid although less 
sensitive. Demonstration of antibody is diagnostic only in unvaccinated 
flocks. Haemagglutination- inhibition (HI) test is       the most widely used for 
measurement of antibodies (Abs) against Newcastle disease virus (Tabidi et 
al., 2004). The haemagglutnation-inhibition test is also used for surveillance 
of chronic Newcastle disease in countries where this form of the disease is 
endemic (Murphy et al., 1999).       
        Enzyme-linked immunosorbent assays (ELISAs) have also been 
employed for the detection of antibodies against NDV. ELISA technique is 
more accurate, sensitive and rapid to perform in detecting Abs against NDV 
compared to HI test although the later is more economic (Tabidi et al., 2004). 
1.10.3 Molecular techniques in the diagnosis of NDV           
        The attraction of molecular-based techniques in ND diagnosis is that they 
may be able to cover all three aspects of Newcastle disease diagnosis 
(detection of virus, characterization, including inference of virulence, and 
epidemiology) quickly, accurately and definitively in a single test (Aldous and 
Alexander, 2001). The most molecular technique used for the diagnosis of ND 
is the reverse transcription- polymerase chain reaction (RT-PCR) because 
NDV has an RNA genome (Alexander, 2003), with subsequent analysis of the 
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product by restriction enzyme analysis, probe hybridization and nucleotide 
sequencing (Aldous and Alexander, 2001). Oligonucleotide probes and viral 
genomic RNA fingerprint analysis have been used to identify and differentiate 
NDV strains, but with limited success. Monoclonal antibodies are now used to 
identify antigenic groups (Seal et al., 2000).  
1.11 Prevention and control   
        There are national and international policies framed to control or prevent 
Newcastle Disease (ND). In some countries it is a notifiable disease requiring 
special control measures, enforced by law. Such enforcement requires clear 
definition of the disease (Survashe and Desmukh, 1998). Where the disease is 
endemic, control can be achieved by good hygiene combined with 
immunization (Murphy et al., 1999).  
1.11.1 Vaccination against Newcastle disease virus  
        For most infectious diseases vaccination is the method of choice for 
prevention. Vaccination for protecting chickens from Newcastle disease is 
routinely practiced through out the world (Rahman et al., 2002). Both live-
virus vaccines containing naturally occurring lentogenic virus strains and 
inactivated virus (injectable oil emulsions) being commonly used (Murphy et 
al., 1999 and Seal et al., 2000).  These vaccines are effective and safe, even in 
chicks, and may be administered via drinking water or by aerosol, eye or 
nostril droplets, or beak dipping. Laying hens are revaccinated every four 
months (Murphy et al., 1999).  
1.11.1.1 Live –virus vaccines 
         These vaccines are prepared from live attenuated viruses and capable to 
infect cells. Strains of virus of low or moderate virulence are used. They 
mimic natural infection and induce all three immune responses (Grimes, 
2002). The superior protection against Newcastle disease afforded by aerosol 
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administration of live-virus vaccines is well documented (McMullin, 1985and 
Tabidi et al., 2004). 
1.11.1.1.1 Mesogenic vaccine strains 
1.11.1.1.1.1 H. Strain  
        Ayar and Dobson in 1946 (cited by Survashe and Desmukh, 1998) 
passaged the field isolate H through chick embryos and attenuated it to use as 
vaccine strain.  
1.11.1.1.1.2 Roakin strain  
       It is naturally occurring mesogenic field isolate and is also used as 
mesogenic vaccine (Survashe and Desmukh, 1998). 
1.11.1.1.1.3 Mukteswar strain 
        Ayer and Dobson in 1940 (cited by Survashe and Desmukh, 1998) carried 
out the attenuation of Ranikhet strain in India and further work was continued 
in India by Hadow and Idnani. At 115 to 126 embryos passage the vaccine is 
used for flock vaccination. Later on after few more passages the strain was 
designated as ‘Mukteswar strain’ and now used in India and other Asian 
countries effectively to control ND (Survashe and Desmukh, 1998). 
Mukteswar strain is an invasive strain, it used as a booster vaccine although it 
can cause adverse reactions (respiratory distress, loss of weight or drop in egg 
production and even death) if used in partially immune chickens. The vaccine 
is usually administered by injection (Grimes, 2002).  
1.11.1.1.1.4 Komorov strain  
        This strain was produced by Dr Heifa Komorov in 1946 by serial 
intracerebral passages of field isolate in ducklings (Survashe and Desmukh, 
1998). This strain is less pathogenic than Mukteswar and used as booster 
vaccine. It is usually administered by injection (Grimes, 2002).  
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1.11.1.1.2 Lentogenic vaccine strains  
1.11.1.1.2.1 F strain  
        The F strain was first reported by Asplin in 1952 (cited by Survashe and 
Desmukh, 1998) in England. It is closely related to B1 strain.  This vaccine is 
usually used in young chickens but suitable for use as a vaccine in chickens of 
all ages (Grimes, 2002).  
1.11.1.1.2.2 Hitchner (HB1) strain 
        The Hitchner (HB1) or B1 (Bulksberg strain) was first described by 
Hitchner in 1948 and used as vaccine (Survashe and Desmukh, 1998).  
1.11.1.1.2.3 LaSota strain  
        This strain was originally isolated by Beaudette in 1946 and used as 
vaccine strain (Survashe and Desmukh, 1998). This strain often causes post 
vaccination respiratory signs and used as a booster vaccine in flocks 
vaccinated with F or B1 (Grimes, 2002).  
1.11.1.1.3 Avirulent vaccine strains 
1.11.1.1.3.1 V4 strain 
        The V4-NDV is an avirulent strain of NDV used as vaccine in chickens 
of all ages. V4-HR is a heat resistant V4, it is thermostable and used in 
chickens of all ages (Grimes, 2002). 
1.11.1.1.3.2 I-2 strain 
            I-2 NDV strain is thermostable and also used in chickens of all ages. 
Thermostable Newcastle disease vaccines exhibit a relative resistance to 
inactivation when exposure to elevated temperature (Grimes, 2002).  
        The mildly virulent B1 and La Sota strains of NDV are currently the 
most widely used efficacious live- virus vaccines for prevention of Newcastle 
disease and are marketed worldwide (Seal et al., 2000; Shuaib et al., 2006 and 
Hofsade et al., 1978).  These live-virus vaccines induce high levels of IgA, 
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IgY and IgM antibodies in sera of newly hatched chicks. They also induce 
local antibody response such as IgA production in the Harderian gland along 
with lacrymal IgM following intraocular inoculation with NDV (Seal et al., 
2000).  
        Vaccination programmes are adopted using live lentogenic and 
mesogenic ND vaccine strains. ND LaSota, ND B1 and ND F strains are 
commonly used for vaccination of young chicks at an early age. In general, 
LaSota vaccine gives better protection than B1 and also has a greater tendency 
to spread from bird to bird. Mesogenic vaccines like ND Mukteswar or 
Komorov strains are used later after eight weeks of age as a booster 
vaccination (Survashe and Desmukh, 1998). Several disadvantages exist, the 
most important that the vaccine may cause disease. Therefore, it is important 
to use extremely mild virus for primary vaccination. Maternally derived 
immunity may prevent successful primary vaccination with live virus 
(Alexander, 2003).  
1.11.1.2 Killed (inactivated) vaccines  
        Since 1930 inactivated ND vaccines have been used for vaccinations 
(Survashe and Desmukh, 1998). The ability of the virus to infect cells has been 
destroyed by treatment with a chemical, radiation or heat. These vaccines 
invoke only a circulating antibody response (Grimes, 2002). Adjuvant 
vaccines enhance the immune response. Now a number of different oil 
emulsion vaccines are available as individual ND killed or combination with 
IB, IBD and are widely in use. Live priming and killed booster vaccination 
strategy is used to maintain high levels of antibody production to prevent 
infection and drop in egg production. In breeder flocks in addition to 
maintaining high levels of ND antibodies in the flock, it will also transfer 
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good level of maternal antibodies to their progeny (Survashe and Desmukh, 
1998).          
       Inactivated oil- emulsion vaccines are not affected by maternal immunity 
as live vaccines and can be used in day- old chicks (Alexander, 2003).  
1.11.1.3 Recombinant or subunit new generation vaccines 
        Several recombinant vaccines have been developed that provide 
protection against Newcastle disease (Seal et al., 2000). The present ND 
vaccines produced by conventional methods are still time-honored and also 
economical. However, using molecular biology technology the understanding 
of pathogenicity and the antigenicity of NDV has enabled cloning of the 
required gene in order to develop new generation vaccines for effective 
control of ND. Further research in developing subunit vaccines or 
recombinant vector ND vaccine is ongoing with encouraging results. 
Recently, a USA-based company has produced USDA approved fowl pox 
virus vector vaccine for the immunization of chickens against ND and fowl 
pox. It protects the birds without post vaccinal respiratory reactions (Survashe 
and Desmukh, 1998).  
1.11.1.4 An ‘in ovo’ vaccination 
        In ovo vaccination is an emerging trend in the poultry industry because of 
its advantages like negligible manpower involvement, induction of neonatal 
resistance and better protection. In ovo vaccination has been proved to be 
effective against Marek’s disease (MD), and infectious bursal disease (IBD) of 
poultry (Manna et al., 2007).  Research in this line for ‘in ovo’vaccination 
with ND vaccine is in progress and the chemically treated ND-B1 EMS 
vaccine strain has been developed. It is immunogenic and non-pathogenic to 
18 day-old embryos. Chicks hatched from ‘in ovo’ vaccinated eggs are 
 28
resistant to ND challenge up to four weeks of age. It is showing good potential 
and the work is still in progress (Survashe and Desmukh, 1998).  
1.11.2 Vaccination Programs   
        Timing of vaccination of broiler chickens can be especially difficult due 
to the presence of maternal antibodies and the short life of the broilers. On the 
other hand vaccination of laying hens always requires more than one dose of 
vaccine to maintain immunity throughout their lives (Alexander, 2003). 
Laying hens are revaccinated every four months (Murphy et al., 1999).  
          Protection against NDV disease can be expected about a week after 
vaccination. Vaccinated birds excrete the vaccine virus for up to 15 days after 
vaccination. Furthermore, infected birds can shed wild-type virus for up to 40 
days even after being vaccinated and may thus represent an important virus 
reservoir (Murphy et al., 1999).  
          In a study designed to compare different routes of Newcastle disease 
vaccination with B1 strain in day-old chicks, Eidsen and Kleven (1976) found 
that aerosol route provide the best protection, followed by the ocular route.  
        Despite the availability of a good number of conventional vaccines using 
strains like B1, F, Clone 30, La Sota, Mukteswar or other 
lentogenic/mesogenic strains of NDV, vaccination failure is common due to 
non-maintenance of cold chain, poor selection of vaccine strain, insufficient 
dose, presence of maternal antibody, and faulty vaccination- schedule (Manna 
et al., 2007). Failure of young chickens to develop expected levels of 
immunity after vaccination for Newcastle disease (ND), infectious bursal 
disease, and other diseases is often due to immune interference from passively 
acquired maternal antibody, which is transferred from hens to progeny via the 
egg yolk (Stone et al., 1992). 
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1.12 Isolation and purification methods of egg antibodies 
         There have been many studies regarding the isolation and purification of 
egg antibodies, especially considering the easy access to this source of 
antibodies and the high levels of specific antibodies present in the egg. 
Various chemicals have been used for the isolation of egg yolk antibodies 
(Hamal et al., 2006).  Several methods can be used, even for large-scale 
purification, of functionally active chicken antibodies from egg yolk 
(Carlander, 2002). Chicken IgY isolated from egg yolk has a molecular 
weight (180 KDa) (Raj et al., 2004 and Bizhanov et al., 2004), which is higher 
than that of mammalian IgG (BIžanov and Jonauskienė, 2003).         
        There are several methods of purification of IgY described. The choice of 
method is a matter of yield and purity desired, final use of the IgY as well as 
material cost and labor skills (Carlander, 2002). Several methods were 
described in the 1950ies for purifying IgY based on the strategy of separation 
of proteins (levitins) from lipoproteins (lipovitellins) and the rest of the yolk 
lipids using extraction with organic solvents with rather low yields of antibody 
(Bizhanov et al., 2004). However, purification methods based on organic 
solvents like chloroform remain in use. Other methods are based on affinity 
chromatography or on dilution of the yolk followed by a freezing-thawing 
process after which the process consists of ion exchange chromatography 
and/or salt precipitations often combining a number of salts like e.g. 
polyethylene glycol (PEG) (Bizhanov et al., 2004 and Hamal et al., 2006), 
dextran sulfate, dextran blue, sodium sulfate, ammonium sulfate caprylic acid 
and sodium citrate. More recently methods combining chloroform removal of 
lipids with ammonium sulfate precipitation techniques have been shown to 
result in a good yield of antibodies of high purity (Bizhanov et al., 2004). 
Bade and Stegemann (1984) used isopropanol and acetone.          
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        Four separation and purification methods in terms of yield, purity, ease of 
use, potential scaling up and immuno-activity of IgY were compared by Akita 
and Nakai in1993. The water dilution method (WD) was compared with three 
other methods, namely, polyethylene glycol (PEG), dextran sulphate (DS) and 
xanthan gum (Xan) techniques. The WD method gave the highest yield, 
followed by DS, Xan and PEG methods, in that order. 9.8 mg IgY/ml egg yolk 
was routinely obtained using the WD method, compared to 4.9 mg IgY/ml egg 
yolk with the popular PEG method with a purity of 94% and 89%, 
respectively. All these methods had no adverse effect on the immuno-
activities of IgY. WD was also found superior in terms of ease of use and 
large scale production of IgY. WD method therefore provides a simple, rapid 
and efficient means of purifying IgY with high activity (Akita and 
Nakai,1993).          
        Isolation of IgY from the yolks of eggs by a chloroform polyethylene 
glycol procedure was done by Polson in 1990. He compared this procedure 
with the polyethylene glycol procedure which is currently being used. Polson 
found that the chloroform - polyethylene glycol method yielded 2.57 times 
more IgY than the conventional polyethylene glycol method (Polson, 1990).          
        It has been demonstrated that the IgY preparation with DS is very 
effective, quick and simple to perform. It is well-suited for use in combination 
with other methods, e.g. ammonium sulfate precipitation (Szabo et al., 1998).          
         Isolation of Immunoglobulin from Egg Yolk was done by using Anionic 
Polysaccharides and the IgY recovery was determined to be 33-74% by means 
of single radial immunodiffusion method when IgY was isolated under the 
optimal conditions (Chang et al., 2000).  Purification of IgY from chicken egg 
yolk by preparative electrophoresis was done by Gee et al (2003). The IgY 
yield was greater than 80% by immunoassay.           
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        Recently, the commercially available IgY purification kits provide a 
quick, simple and efficient method to extract IgY from egg yolk. They usually 
contain delipidation and precipitation reagents and require multiple step 
methods.  
        Chicken immunoglobulin Y( IgY) does not bind bacterial Fc receptors 
such as staphylococcal protein A or streptococci protein G or mammalian Fc 
receptors, as do most mammalian Immunoglobulins (Raj et al., 2004). Thus, 
classical affinity chromatography methods such as Protein A and Protein G 
cannot be used to purify IgY from egg yolks. In most of the work, enzyme 
linked immuosorbent assays (ELISA) were used to study the IgY activity. The 
ELISA principle is that an antigen is coated to a surface. The desired antibody 
in a sample is then allowed to attach itself to the antigen. The bound sample 
antibody is then detected by another, labeled antibody. The amount of the 
sample antibody can then be correlated to the labeled antibody in the assay 
(Carlander, 2002).  
1.13 IgY as an alternative to mammalian antibodies  
        The immunoglobulin of egg yolk differs from mammalian IgG in the 
molecular size (larger), isoelectric point (more acidic), and has no binding 
ability with mammalian complement and protein A (Hatta et al., 1990). IgY 
can be used as an alternative to mammalian antibodies normally used in 
research, and its use in immunotherapy has recently been proposed. Compared 
to mammalian antibodies, IgY possesses several biochemical advantages and 
its simple purification from egg yolk prevents a stressful moment in animal 
handling, as no bleeding is necessary (Carlander, 2002). Due to present-day 
constraints regarding animal experimentation, chicken yolk IgY offers an easy 
and acceptable alternative for production of antiserum. Moreover, the active 
transport of IgY from serum to the egg occurs in a higher concentration than 
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in serum. Thus, more antibodies can be produced per month than in rabbits 
(Raj et al., 2004).  
        IgY is also known as γ-livetin and exists in egg yolk together with other 
two water- soluble proteins, α- livetin (chicken serum albumin) and β- livetin 
(α2 glycoprotein) and various lipoproteins (LDL and HDL) which are the 
major components of the egg yolk (Hatta et al., 1990). The major problem in 
the isolation of chicken antibodies (IgY) is the removal of lipids, which are 
present at high concentration in egg yolk (Stålberg and Larsson, 2001 and 
Jensensius et al., 1981). Egg yolk contains approximately 50% water. The dry 
weight of egg yolk is made up of 2/3 of lipids, and 1/3 of proteins (Stålberg 
and Larsson, 2001).  
        Egg can be stored for up to one year at 4°C prior to IgY purification 
(Haak-Frendscho, 1994). Typically, each egg will contain about 90-100mg of 
total IgY (Carlander, 2002 and Haak-Frendscho, 1994), and the specific 
antibody generally comprises 1-10% of that total, or about 1-10mg of specific 
IgY per egg (Haak-Frendscho, 1994).         
        The use of chicken egg yolk as a source for antibody production 
represents a reduction in animal use as chickens produce larger amounts of 
antibodies than laboratory rodents. It also makes it possible to eliminate the 
collection of blood, which is painful for the animal. The European Centre for 
the Validation of Alternative Methods (ECVAM) recommends that yolk 
antibodies should be used instead of mammalian antibodies for animal welfare 
reasons (Carlander, 2002). In 1999, the IgY-technology was approved as an 
alternative method for supporting animal welfare by the Veterinary Office of 
the Swiss Government, Office Vétérinaire Fédéral (Schade et al., 2005).  
        Chicken eggs have long been recognized as a potential source of 
pharmaceutical product and represent a low cost, high-yield bioreactor system. 
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Egg white and egg yolk are sterile; their proteins can be fractionated with 
different technologies and combined with the egg industry’s capacity to 
produce thousands of eggs per day (Narat, 2003).  
        As a laying hen produces approximately 20 eggs per month, over two 
gram IgY per month can be isolated. The IgY concentration in chicken serum 
is approximately five-seven mg/ml, therefore two gram of egg yolk IgY 
corresponds approximately to the IgY content of 300 ml of serum or 600 ml of 
blood. Only larger mammals can produce equal amounts of serum antibodies 
and compared to rabbits, the chicken antibodies are ten times less expensive 
(Carlander, 2002).  
        Highly conserved mammalian proteins sometimes fail to illicit a humoral 
immune response in animals, such as rabbits, that are traditionally used for 
generating polyclonal antibodies. Since chicken IgY does not cross-react with 
mammalian IgG and does not bind bacterial or mammalian Fc receptors, non-
specific binding is reduced, and the need for cross-species immunoabsorptions 
is also eliminated (Haak-Frendscho, 1994).  
 1.14 Application of IgY antibodies   
        There is an increasing interest in the use of chicken egg yolk for 
polyclonal antibody production for practical and economical reasons and 
chicken egg yolk antibodies (IgY) have been applied successfully for 
scientific, diagnostic, prophylactic and therapeutic purposes (Bizhanov et al., 
2004 and BIžanov and Jonauskienė,2003).  
        New application in human and veterinary medicine including strategies 
for the treatment of Helicobacter pylori infection or fatal intestinal diseases in 
children, particularly in poor countries, for reducing the use of antibiotics, 
and, in Asia and South America, for producing Abs against snake, spider and 
scorpion venoms (Schade et al.,2005).  
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        Makvandi and Fiuzi found that hepatitis B virus (HBV) vaccine was 
immunogenic in hens and ELISA using the purified anti-HBsAg from the egg 
yolks was able to detect the HBsAg in the sera of patients infected with 
hepatitis B virus (Makvandi and Fiuzi, 2002).  
         Passive immunization by oral administration of specific antibodies has 
been an attractive approach against gastrointestinal (GI) pathogens in both 
humans and animals. Oral administration of IgY has proved successful for 
treatment of a variety of GI infections, such as bovine and human rotaviruses, 
bovine coronavirus, Yersinia ruckeri, enterotoxigenic Escherichia coli, 
Salmonella spp., Edwardsiella tarda, Staphylococcus, and Pseudomonas 
(Yoshinori and Kovacs-Nolan, 2002).  
        A study done in 2006 demonstrated that hyperimmunized yolk can be 
raised to purify antibodies which can then be used to control infectious bursal 
disease (IBD) infected commercial layers, commercial broilers, broiler 
breeders and indigenous birds (Malik et al.,2006) .  
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CHAPTER TWO 
MATERIALS AND METHODS  
 
2.1 Collection of samples  
        Laying bovan chicken aging 5-8 months were used to collect eggs. The 
flock was vaccinated with Komorov strain of NDV. The last dose of the 
vaccine was at four month old. Ninety six egg samples were collected and 
placed at 4°C till examined. 
2.2 Extraction of IgY from Egg Yolk by dextran sulphate method  
        Extraction was carried out by the protocol outlined by Jensenius et al  
( 1981).  
2.2.1 Reagents 
Tris buffered saline containing 0.1% sodium azide (TBS) 
 10% (w/v) dextran sulphate in TBS 
1M calcium chloride in TBS  
Sodium sulphate, anhydrous.  
36 %( w/v) sodium sulphate. 
2.2.2 Materials required  
        Clean Petri dish, forceps, 50ml graduated centrifuge tubes, glassware 
such as flasks and beakers, pipetting device with disposable pipette tips and 
dialysis tube with molecular weight cut off 12-14000 Dalton (Medicell 
International Ltd,UK).  
2.2.3 Isolation procedure         
To extract IgY from the egg yolk, the egg yolk was taken out of the         
eggshell and placed in a clean Petri dish. The egg yolk membrane was broken 
with the help of forceps. The yolk was allowed to run into a 50ml graduated 
centrifuge tube, and its volume was noted after it settled down. Tris buffered 
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saline (TBS) containing 0.1% sodium azide was added to the yolk to bring the 
volume to 50ml and mixed. Diluted yolk suspension was centrifuged at 2000 g 
for 20 min at 20°C. Pellet was discarded and supernatant was saved. 
Supernatant was mixed with 3 ml of 10% dextran sulphate solution and 7.5 ml 
of 1M calcium chloride solution; incubated for 30 min and then centrifuged as 
above. Clear supernatant was saved. The precipitate was resuspended in 50 ml 
of TBS and recentrifuged. The two supernatants were pooled and the final 
pellet was discarded. If the first supernatant was cloudy, more dextran 
sulphate and calcium chloride were added and incubation and   centrifugation 
were repeated. TBS was added to the pooled supernatants to the final volume 
of 100 ml and 20 g of anhydrous sodium sulphate was slowly added, stirred to 
dissolve and incubated at room temperature for one hour then centrifuged at 
2000 g for 20 minutes at 25°C. The supernatant was discarded. The protein 
precipitate was redissolved in TBS to the final volume of 10 ml. Sodium 
sulphate solution was added to make a final concentration of 9% (w/v),(=2.5 
ml of the 36% Sodium sulphate solution) ,mixed and incubated for one hour at 
room temperature. After incubation period, the mixture was centrifuged at 
2000g for 20 minutes at 25°C and the pellet was discarded. Sodium sulphate 
solution was added to the saved supernatant to make a final concentration of 
14 %( w/v), (=3.9 of the 36% Sodium sulphate solution), mixed and incubated 
for one hour at room temperature. After incubation period, the mixture was 
centrifuged at 2000g for 20 minutes at 25°C. The supernatant was discarded 
and the Pellet (immunoglobulin precipitate) was redissolved in 5 ml TBS and 
dialyzed against TBS with dialysis volume approximately 50 times larger than 
the sample volume for 24 hours. After dialysis, the sample was poured in 
sterile 5ml tube and stored at 4°C till use. Specificity of IgY to NDV was 
determined by standardized indirect ELISA (In- house ELISA). 
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2.3 Determination of the specificity of the extracted IgY to NDV by 
standardized indirect Enzyme -Linked Immunosorbent Assay (ELISA) 
(In-house ELISA)  
2.3.1 Materials required:  
96-well Flat-bottomed ELISA plates (Nunc-Immunoplate, Denmark) 
NDV vaccine (Komorov strain) as coating antigen (Central Veterinary 
Research Laboratories center, Khartoum, Sudan) 
Samples under test (extracted IgY) 
0.05M Carbonate buffer, pH 9.6  
0.15M Phosphate buffered saline (PBS), pH 7.2  
0.05M Phosphate-citrate buffer, pH 5.0   
Tween 80 
Bovine serum albumin (BSA) (Sigma, USA) 
Horseradish peroxidase-conjugated rabbit anti-chicken IgG (Nordic 
immunological laboratories, the Netherlands) 
O-phenylenediamine dihydrochloride (OPD) (Sigma immuno chemicals, 
USA). 
30% hydrogen peroxide solution  
1N hydrochloric acid (HCl) 
Positive control serum (prepared in the lab) 
Negative control serum (PBS buffer was used) 
Single and multichannel pipettes and tips  
V-bottom troughs   
ELISA reader  
2.3.2 Preparation of ELISA solutions 
2.3.2.1 Carbonate Coating buffer 
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        Coating  buffer  used  for  antigen  dilution  was 0.05M Carbonate buffer,  
pH 9.6. It was prepared by dissolving 1.59g sodium carbonate (Na2CO3) and 
2.93g sodium hydrogen carbonate (NaHCO3) in one liter of distilled water 
then pH was adjusted.  
2.3.2.2 Washing buffer 
        0.15M Phosphate buffered saline (PBS), pH 7.2 was prepared by 
dissolving 8.00g sodium chloride (NaCl), 0.20g potassium chloride (KCl), 
1.15g di-sodium hydrogen phosphate (Na2HPO4) and 0.20g potassium di 
hydrogen phosphate (KH2PO4) in one liter of distilled water and the pH was 
adjusted.  
2.3.2.3 Substrate buffer 
        0.05M Phosphate-citrate buffer, pH 5.0 was prepared by adding 25.7ml 
of 0.2M di-sodium hydrogen phosphate (Na2HPO4) to 24.3ml of 0.1M citric 
acid and completed to 100ml by adding 50ml deionized water. The pH was 
adjusted. This buffer was used for substrate preparation.  
2.3.2.4 Blocking solution 
        Blocking solution was 2% Bovine serum albumin (BSA) in PBS  
(website 1). 
2.3.2.5 The diluent 
        The diluent for primary and secondary Abs was PBS containing 0.5% 
BSA and 0.05% Tween 80 (PBS- Tween) (website 2). 
2.3.2.6 The conjugate 
        The conjugate Horseradish peroxidase-conjugated rabbit anti-chicken 
IgG was purchased from Nordic labs (Tilburg, The Netherlands). It was 
lyophilized and was reconstituted by adding 1ml sterile distilled water and that 
gave 1ml of IgG protein with concentration of 4.6mg/ml. The reconstituted 
conjugate was divided into small aliquots each one contains 0.1ml (100 µL) 
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kept frozen at -20°C. Prior to use, an aliquot was thawed slowly at ambient 
temperature and used to prepare working dilution by adding sterile Phosphate 
buffered saline (PBS), pH 7.2.  
2.3.2.7 The substrate 
        The substrate O-phenylenediamine dihydrochloride (OPD) was used. The 
30mg substrate tablet was dissolved in 75ml 0.05M Phosphate-citrate buffer, 
PH 5.0 to give a concentration of 0.4mg/ ml as recommended by the 
manufacturer. 40 µL of fresh 30% hydrogen peroxide per 100ml of substrate 
buffer solution was added immediately prior to use. 
2.3.2.8 Stopping solution 
        The 1N HCl was used for stopping the reaction. 85.85 ml of 36%HCl 
was completed to one liter by adding distilled water to give 1N HCl. 
 2.3.3 Preparation of hyper-immune serum against NDV as positive 
control 
2.3.3.1 The vaccine:  
        The freeze-dried live chick-embryo adapted vaccine containing Komorov 
strain (K) of NDV was used. The vaccine was kindly supplied by the Viral 
Vaccine Department; Central Veterinary Research Laboratories center 
(Khartoum Sudan). It was kept at 4°C till use.  
2.3.3.2 Immunization of chickens 
        Four laying hens from ND-vaccinated flocks (with Komorov strain of 
NDV) were boosted intramuscularly in the breast with 0.2ml of 1:1000 and 
1:100 respectively with two weeks interval .Two weeks later, 3ml blood was 
collected from each hen from the wing vein using 5ml sterile syringes. Blood 
was then left in syringes undisturbed at room temperature for three hours. Any 
expressed serum was collected and stored in Eppen Dorf tubes at 4°C to be 
tested by haemagglutination- inhibition test to for NDV antibody titeration.  
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2.3.3.3 Haemagglutination- inhibition test 
2.3.3.3.1 Viral antigen 
        The vaccine containing Komorov strain (K) of NDV was titrated to be 
used as the antigen in the HI test. The standard amount of Newcastle disease 
virus used in the haemagglutination inhibition (HI) test was 4HA units. 
2.3.3.3.2 Determination of 4HA units of Newcastle disease virus antigen 
by haemagglutination test:  
2.3.3.3.2.1 Materials required  
96-well microtitre plates, U-shaped  
1% chicken red blood cell (RBC) solution 
Phosphate-buffered saline (PBS), pH 7.2  
2.3.3.3.2.2 Preparation of chicken red blood cells (CRBCs) 
        Five ml blood was collected from an adult bird in a test tube containing 
0.5 ml of a 4 % sodium citrate as anticoagulant. The blood was centrifuged at 
1500 rpm for 5 minutes and the supernatant was discarded. Packed RBCs 
were resuspended in 10 ml of phosphate buffered saline (PBS).The process of 
RBCs washing in PBS was repeated until a clear supernatant was obtained. 
The packed RBCs was resuspended in PBS to give 1 % RBCs suspension.  
2.3.3.3.2.3 Haemagglutination (HA) titration procedure 
        Fifty µl of PBS (pH 7.2) was added to all wells in the first four rows 
except column 1. 100 µl of the antigen was added to column1 wells. Using 
multichannel pipette, serial 2-fold dilution was made by transferring 50 µl 
from the first wells of lettered rows to successive wells. The final 50 µl was 
discarded. The D row was prepared as RBC control wells by adding 100 µl of 
PBS (No antigen was added). 50 µl of 1% RBC suspension was added to all 
wells. Then plate was shaken for about five seconds on a microshaker, then 
incubated at room temperature and read after 30  minutes or as soon as the 
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RBCs in the control wells had settled. The end-point was taken as the dilution 
in the last wells that showed complete (100 percent end point) 
haemagglutination. The HA titer was the reciprocal of that value. The antigen 
dilution (4HA units of Newcastle disease virus antigen) was calculated by 
dividing the HA titer by 4. The diluted antigen containing 4HA units was 
stored at 4°C and used within the same day (Figure 5). 
2.3.3.3.2.4 Haemagglutination- inhibition test procedure 
2.3.3.3.2.4.1 Materials required  
U-bottom microwell plates and covers 
Phosphate buffered saline (PBS), PH 7.2  
1% chicken red blood cell (RBC) solution  
V-bottom reagent trough  
50 µL single and multichannel pipettes and tips  
Recording sheet.  
Newcastle disease virus antigen diluted to 4 HA units 
2.3.3.3.2.4.2 Test procedure 
        Recording sheet was filled in to record how samples will be dispensed 
into  microwell  plate.  Rows from A to F  was  used.  50  µL  of  PBS was        
dispensed into all wells. 50µL of each serum sample was dispensed into each 
well of the first column (ABCDF) then a multichannel pipette was used to 
make two-fold serial dilutions along the rows, the last 50µL was discarded. 
The wells of row G was prepared as negative control wells by adding 100 µL 
of PBS (no Abs added). 50 µL of the 4HA dilution of antigen was added to all 
wells including the control. Plate was shaken to mix the reagents, covered 
with a lid and allowed to stand for 30 minutes at room temperature. 50 µL of 
1% washed red blood cells was distributed into all wells including the control, 
covered  and  incubated  at  room  temperature  for  45  minutes  and the 
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results were read. The titer of haemagglutination-inhibiting antibodies was the 
highest serum dilution that inhibited the agglutination of 75% −100% of red 
blood cells and expressed as the reciprocal of that dilution (Figure 6). 
2.3.3.3.4 Production of positive control serum   
       Three of chickens immunized by ND vaccine gave antibody titer (7 log2) 
in HI test and were selected to be used as positive controls.  10ml blood was 
collected from each selected hen from the wing vein using 10ml sterile 
syringes and immediately poured into a sterile centrifuge tubes. Blood was 
allowed to clot at room temperature (about one hour) and left overnight at 
4°C. Clot was detached from walls of the container and all clot free serum was 
poured into a centrifuge tube, clot was centrifuged for 30min at 2500g at  4°C 
and any expressed serum was removed and pooled with the first liquid. The 
pooled sera were centrifuged for 20 min at 1500g at 4°C. Sera obtained were 
pooled together (about 15ml), divided into small aliquots and stored at -20°C 
tell use.  
2.3.4 Selection of ELISA plates  
        High protein-binding capacity polystyrene 96-well Flat-bottomed ELISA 
plates from Nunc (Denmark) were used since low-protein binding capacity 
plates yield low signal or inconsistent data. 
2.3.5 Standardization of ELISA reagents  
        Optimal dilutions of the antigen and the conjugate were estimated by 
checkerboard titration as follow:  
2.3.5.1 Antigen preparation  
        The  freeze - dried,  live,  chick- embryo  adapted  vaccine  containing             
Komorov strain (K) of NDV (Centre of Veterinary Research Laboratories, 
Sudan) was used as coating antigen. The antigen was lyophilized. It was 
reconstituted in one ml carbonate buffer and then diluted as specify. 
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Fig. 5: Haemagglutination test plate.  
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 Fig. 6: Hemagglutination- inhibition test plate. 
Rows (ABCDEF) contain PBS, serum, antigen and 1% chicken RBCs. Row G 
contains PBS, 4HA units antigen and 1% chicken RBCs as control. 
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2.3.5.2 Titration of the antigen  
        Two flat-bottomed polystyrene microtiter plates were coated with 
100µl/well of increasing dilutions of antigen, from1:10 to1:80 in the first plate 
and from 1:90 to1:160 in the second plate, each row contained one dilution. 
The carbonate buffer was used for antigen dilution. The plates were incubated 
for one hour at 37°C and then over night at 4° C, and washed three times with 
PBS. 
2.3.5.3 Titration of the serum  
        One ml of hyperimmune serum was diluted in nine ml PBS-Tween to 
make 10ml of dilution 1:10. In each one of the two precoated plates, 
100µl/well of diluted serum was distributed in columns 1- 3, 5- 7 and 9- 11. 
Negative control wells were prepared in columns 4, 8 and12 by adding 
100µl/well PBS without serum. Plates were incubated for one hour at 37° and 
then washed three times with PBS.                                                                         
2.3.5.4 Titration of the conjugate   
       The secondary antibody, a peroxidase-conjugated rabbit anti-chicken 
Immunoglobulin was prepared in concentrations of 1:1000, 1:5000 and 
1:10000 (diluted in PBS-Tween) and distributed in 100 µl volume per well in 
each plate (1:1000 from column1 to 4, 1:5000 from column 5 to column 8 
and1:10000 from column 9 to column 12). Plates were incubated for one hour 
at 37° C. The plates were then washed three times with PBS (Figure 7).  
Finally, 100µl/well of peroxidase substrate (OPD) was added to each well and 
incubated for 20 minutes at room temperature. The optical density (OD) was 
read with the ELISA reader at 450nm.  
        From the checkerboard experiments the optimal dilutions were found to 
be 1:50 for the antigen and 1:5000 for the conjugate (Figure 8). 
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Fig. 7: Checkerboard titration plate format. 
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Fig. 8: Checkerboard titration plate. 
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2.3.6 Indirect ELISA for detection of presence of NDV antibodies in egg 
yolk (In-house ELISA) 
        Flat-bottomed ELISA plate was coated by dispensing 100 µL of antigen 
diluted to 1:50 in 0.1 M carbonate buffer pH 9.6 into all wells. The plate was 
incubated at 37°C for one hour and then over night at 4°C. The plate was then 
washed by filling all wells with 200 µL PBS using multichannel pipette. The 
plate was shaked gently and the content was poured out, the excess wash 
buffer was removed by banging the plate upside down on dry paper towels. 
Washig procedure was repeated three times. The plate was then blocked with 
150 µL of 2 % bovine serum albumin in PBS for one hour at 37°C. The 
blocking was done to prevent the antibody to attach to any possible unbound 
sites then plate was washed three times with PBS as above. 100 µL of 
undiluted samples were added to wells in column 1. All test samples were 
diluted to 1:100 by adding 10 µL of sample to 990 µL of diluent and added to 
wells in column 2. Two- fold dilutions for each sample was made across the 
corresponding row to give 1:200, 1:400……etc using multichannel pipette 
starting at column 2 through to column 10. Tips used were changed after each 
transfer. The column 11 was used as a positive control. 1:100 dilution of the 
positive control serum was prepared (as done for samples above) and 100 µL 
of diluted positive control serum was added to each well in column 11. The 
column 12 was used as a negative controls by adding 100 µL/well PBS, no 
serum was added. The plate was incubated for one and a half hour at 37°C and 
was washed three times with PBS as previously described. Then 100 µL of the 
conjugate, (rabbit anti-chicken IgG-HRP) diluted to1:5000 in PBS-Tween was 
added to the plate and the plate was incubated for one hour at37°C. The plate 
was washed as previously described. The OPD, a horseradish peroxidase 
substrate was prepared and 30 µL of 30% hydrogen peroxide (H2O2) per 
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100ml of substrate buffer solution was added. 100 µL/well OPD was then 
added into plate and the plate was covered. The reaction was stopped after 15 
minutes by addition of 100 µL of 1N HCl. The plate bottom wiped to dry.  
The intensity of color development was determined by measuring absorbance 
using a micro-ELISA reader (Rayto, RT- 6100, China) equipped with a 492 
nm filter.  
2.3.7 Detection of maternal specific NDV IgY using NDV ELISA test kit 
(comparative study) 
2.3.7.1 Reagents included in the ELISA test kit 
NDV coated plates  
NDV positive control 
Negative control  
Goat anti- chicken horseradish peroxidase conjugate 
Sample diluent buffer 
TMB substrate  
Stop solution  
2.3.7.2 The test procedure 
       NDV antibody test kit (Flockchek-IDEXX, USA) was used to detect NDV 
antibody in chicken egg yolk. The test was performed as described by the 
manufacturer with some modifications. In brief, 100µl of undiluted negative and 
positive control were put into well AI, 2 and A3, 4 (of the coated plates) 
respectively. In the rest of the plate, 100µl of undiluted samples were added to 
each used well. The plate was incubated for 30 minutes at room temperature. 
Each well in the plate was then washed three to five times with approximately 
350µl deionized water. 100µl of (goat) antichicken horseradish peroxidase 
conjugate was dispensed into each well and incubated for 30 minutes at room 
temperature. The plate was washed as mentioned above. 100µl of TMB substrate 
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solution were dispensed into each well then incubated for 15 minutes at room 
temperature. 100µl of stop solution were dispensed into each well to stop the 
reaction. The absorbance of the control serum and serum samples was recorded 
using the plate reader at 650nm. The software (Flockchek-IDEXX, USA) was 
used for calculation of sample to positive (S/P) values.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51
 
 
 
 
Fig. 9: Standardized indirect ELISA plate 
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CHPTER THREE 
RESULTS  
3.1 Detection of presence of NDV antibodies in the egg yolk by 
Standardized indirect ELISA 
3.1.1 Interpretation of results 
3.1.1.1 Determination of the cut-off value (the negative- positive 
threshold) 
The cut-off value used for determination the presence or absence of 
antibodies to NDV in samples (positive or negative) was the positive- negative 
threshold which calculated as three standard deviations (SD) above the mean 
optical density of the negative control (m NC) as described by Snyder et al 
(1983): 
The positive- negative threshold = m NC+ 3SD 
All test samples values above the cut-off value were reported as positive.  
3.1.1.2 The antibody titer 
        The antibody titer was expressed as the reciprocal of the lowest dilution 
giving an absorbance three times higher than the standard deviation of the 
negative control.  
Results of each sample (OD, positive or negative and titers) are shown in 
Table (1) appendix 1.  
3.2 Antibody titration by indirect ELISA kit  
For the assay to be valid, the difference between the positive control mean and 
the negative control mean should be greater than 0.075.  
        The relative amount of antibodies in tested samples was determined by 
calculating the ratio of sample to positive control (S/P ratio). 
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 S/P =          sample OD – negative control mean   
            positive control mean - negative control mean  
 
        Samples with S/P ratio of less than or equal to 0.2 were considered 
negative and those with S/P ratio greater than 0.2 were considered positive. 
The endpoint titers were calculated using the following equation: 
Log10titre = 1.09 (Log10 S/P) +3.36 
 
Results of each sample (OD, positive or negative and titers) are shown in 
Table (2) appendix 2.  
 
Log2 of each sample titer was calculated using computer soft were then 
samples were grouped in titer groups as shown in table (3) and figure (10) for 
the In-house ELISA and in table (4) and figure (11) for the indirect ELISA kit. 
 
Table (5) shows comparative results between the In-house ELISA and the 
indirect ELISA kit. 
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Table 3: Standardized indirect ELISA titer groups (In- house ELISA) 
Titer group Samples 
count 
Titer 
(log 2) 
1 12 8.643 
2 7 9.643 
3 15 10.643 
4 16 11.643 
5 23 12.643 
6 17 13.643 
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Fig. 10: Standardized indirect ELISA titer groups 
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Table 4: NDV ELISA test kit titer groups 
Titer 
group 
Samples 
count 
Titer 
(log 2) 
1 1 10.838 
2 8 11.513 – 11.963 
3 49 12.009 – 12.987 
4 33 13.154 –  13.949 
5 1 14.171 
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Fig. 11:  NDV ELISA test kit titer groups 
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Table 5: Comparison between results obtained from the standardized indirect 
ELISA (In- house ELISA) and from the NDV ELISA test kit  
 Samples 
number 
Positive 
samples 
Negative 
samples 
Max 
Titer 
(log 2) 
Min 
Titer 
(log 2) 
Samples 
number 
with 
Titers (10 – 13) 
Standardized 
ELISA 
96 96 
(100%) 
0 13.643 8.643 
 
71 
(73.3%) 
ELISA 
kit 
92 92 
(100%) 
0 14.171 10.838 91 
(98.8%) 
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CHAPTER FOUR 
DISCUSSION 
        In this study the egg yolk antibodies were extracted by the dextran 
sulphate method. Szabo et al (1998) demonstrated that the IgY preparation 
with dextran sulphate is very effective, quick and simple to perform. This 
procedure does not give completely pure IgY but the preparation is free from 
other classes of immunoglobulin because of their absence from yolk as stated 
by Hamal et al (2006) who reported that IgY is present predominantly in the 
egg yolk, whereas IgA and IgM are present in the egg white and with 
Carlander (2002) who reported that IgA and IgM are not present in the yolk.  
        Chicken immunoglobulin Y (IgY) does not bind bacterial Fc receptors such 
as staphylococcal protein A or streptococci protein G or mammalian Fc receptors, 
as do most mammalian Immunoglobulins as reported by Raj et al (2004). Thus, 
classical affinity chromatography methods such as Protein A and Protein G 
cannot be used to purify IgY from egg yolks. Further purification can be carried 
out using the gel filtration on Sephadex G 200.  Generally, the choice of method 
is a matter of yield and purity desired, final use of the IgY as well as material cost 
and labour skills.  
        In the present study presence of NDV antibodies in the egg yolk extracts 
(the positive results) indicates transfer of maternal antibodies from hen׳s 
serum to the egg yolk and specificity of the antibodies to NDV. 
         Typically, each egg will contain about 90-100mg of total IgY and the 
specific antibody generally comprises 1-10% of that total, or about 1-10mg of 
specific IgY per egg as reported by Haak-Frendscho (1994) and Carlander 
(2002). Hamal et al (2006) reported that the IgY levels, total or antigen-
specific, in the dams’ plasma or eggs were found to be a direct indicator of 
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maternal antibody transfer to the chicks’ circulation, with an expected 
percentage transfer of approximately 30%. 
        The size of the collected eggs was not the sam and Carlander (2002) 
reported that the amount of IgY transported is independent of egg size. The 
populations of IgY are transported according to their concentration in the 
maternal serum. There is no selection nor destruction of IgY during transport. 
Thus titers of the hen’s serum antibodies to ND and the passive antibodies in 
chicks could be calculated indirectly by determining the titers of IgY in yolks.   
         Although maternal antibodies provide passive immunity in young chicks 
for a few weeks after birth and considered to be protective, they also interfere 
with the chick’s active response to vaccination. Maternal antibody interferers 
with active immunization, presumably by sequestering vaccine antigen or 
restricting replication of vaccine virus, this was reported by Stone et al (1992). 
Rahman et al (2002) reported that maternal antibody neutralizes the 
introduced vaccine antigen rendering the vaccine ineffective and immune 
response was nil at high titer of maternal antibody and thus, taken into 
consideration during primary vaccination. 
        In this study high titers of NDV specific antibodies was measured in eggs 
of immunized hens collected during the first month after the last dose of 
vaccination (five months old). This booster dose in mothers developed high 
titers of NDV specific antibodies that peak at about three to four weeks after 
vaccination and these results substantiate the study reported by Alexander 
(2003). However the titers then slowly decrease as reported by Butcher and 
Miles (2003) and this explain the low titers in some egg yolk extracted from 
eggs of eight month old hens (three months after vaccination). This suggests 
the importance of revaccination of laying hens every four months as reported 
by Murphy et al (1999). Therefore, extraction of maternally derived NDV 
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antibodies will facilitate accurate monitoring of ND vaccination programmes. 
Furthermore antibody titer should not necessarily be high but should be in 
close range with the same herd. 
As we demonstrated a considerable variation in maternal NDV specific 
antibody titer by both ELISA methods, we were able to place the ELISA 
results into NDV antibody ELISA titer groups. This lend us to suggest that 
determination of antibody titer in yolk or sera of laying hens or parent stock 
can facilitate batching of the breeding flock or laying hens into groups. This 
because egg or sera with low titer or no antibodies to the specific disease 
might constitute a threat of that disease as the degree of resistance induced by 
any vaccine is subject to the level of challenge present in poultry farms.  
Intriguingly, in the present study the NDV antibody titers obtained in 
some of yolk extracts were much higher than the titer obtained from our 
prepared hyper-immune serum and this is in agreement with Schade et al 
(1996) who reported that the data available indicate that IgY is more highly 
concentrated in yolk than it is in serum and also in agreement with Raj et al 
(2004) who reported that the active transport of IgY from serum to the egg 
occurs in a higher concentration than in serum. 
        As a comparison, antibody titers obtained from commercial NDV 
antibody test kit were higher than those obtained from our standardized 
indirect house ELISA. This result indicates that the sensitivity of the NDV 
antibody test kit was higher than the standardized indirect (In- house) ELISA. 
In both tests, most samples have titers between 10 log 2 and 13 log 2. Both 
results were based on the optical density rather than absolute values (ng 
IgY/ml). Nevertheless, indirect ELISA remains an important tool to monitor 
the efficacy of vaccination where immunity is measured by antibody response 
as reported previously by Snyder et al (1983).          
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        On conclusion, in this study maternally derived antibodies present in the 
egg yolk specific to NDV were present in high titers that confer protection 
during early weeks of life of hatching chicks. Extraction of maternally derived 
specific antibodies from egg yolk will facilitate accurate monitoring of ND 
vaccination programmes. 
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CONCLUSION 
1- Dextran sulphate method for the extraction of egg yolk IgY antibodies was 
simple to perform and gave high recovery and purity of egg yolk IgY. 
2- High titers of NDV specific IgY were detected in egg yolk of vaccinated 
hens, both by our In- house ELISA and the commercial NDV antibody ELISA 
kits. 
3- Results obtained by In- house ELISA assay were comparable to the results 
obtained by the commercial NDV antibody ELISA kits. 
4- The high titers of maternally derived NDV specific IgY could confer 
protection in newly hatched chicks. 
5- Extraction of maternally derived NDV specific antibody from egg yolk of 
vaccinated hens will facilitate accurate monitoring of ND vaccination 
programmes. 
6- Indirect ELISA assay can be used to monitor the efficacy of ND vaccines in 
poultry farms. 
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RECOMMENDATIONS 
 
1- Dextran sulphate method for extraction of egg yolk IgY is simple procedure 
to isolate maternally derived IgY to evaluate maternal immunity in poultry 
farms. 
2- Indirect In-house ELISA could be elaborated to be routinely used instead of 
expensive commercial ELISA kits to monitor the efficacy of vaccination 
where immunity is measured by antibody response. 
3- Extraction of maternally derived specific antibodies will facilitate and 
accurate monitoring of vaccination programmes in poultry farms. 
4- Determination of antibody titer in egg yolk or sera of hens and parent stock 
can facilitate separation these flocks into groups according to their immune 
status to reduce losses during epidemics. 
5- Barring procedural errors in performing ELISA assay, scoring of samples 
with optical density reading skirting the cut off range are problematic 
compared to data expressed in absolute values derived from calibration curve. 
Absolute values are meaningful and acceptable and we recommend that the 
expression of ELISA assay in absolute values in future work.  
 
 
 
 
 
 
 
 
 
 63
REFERENCES 
 
Akita, E.M. and Nakai, S.1993. Comparison of four purification methods for the 
production of immunoglobulins from eggs laid by hens immunized with an 
enterotoxigenic E. coli strain. J. Immunol Methods. 160:207-214.  
 
Aldous, E. W. and Alexander, D. J. 2001. Detection and differentiation of Newcastle 
disease virus (avian paramyxovirus type 1). Avian Path. 30: 117– 128.  
 
Alexander, D J. 1988. Newcastle Disease, Kluwer Academic Publishers, London. 
 
Alexander, D. J. 1997. Newcastle disease and other avian Paramyxoviridae 
infections. In B.W. Calnek, H.J. Barnes, C.W. Beard, L.R. McDougald and 
Y.M. Saif (Eds.). Diseases of Poultry. 10th edn. pp 541– 570. Ames: Iowa 
State University Press.  
 
Alexander, D. J. 2003. Newcastle disease and other paramyxovirus infections. In 
Y.M. Saif, H.J. Barnes, J.R. Glisson, A.M. Fadly, L.R. McDougald,D.E. 
Swayne (eds.). Diseases of Poultry. 11th edn. pp 63- 82. Blackwell publishing. 
USA. 
 
Ask, B.; van der Waaij, E.H.and van Arendonk, J.A.M. 2004. Genetic implications 
of neonatal immune ontogenesis and challenge for immune response and 
population health. In: Proceedings World's Poultry Congress. Instanbul. 
Turkey. 8-13 June 2004. 
 
 64
Bade, H. and Stegemann, H. 1984. Rapid method of extraction of antibodies from 
hen egg yolk. J. Immunol. Methods 72:421–426. 
 
Bell, J.G.; El Hakim El Alaoui, M. and Jaouzi, T. 1991. An ELISA kit for antibodies 
against Newcastle disease virus. World Animal Review 69: 59–63. 
Bizhanov, G.; Jonauskiene, I. and Hau, J. 2004. A novel method, based on lithium 
sulfate precipitation for purification of chicken egg yolk immunoglobulin Y, 
applied to immunospecific antibodies against Sendai virus. Scand. J. Lab. 
Anim. Sci. 31:121-130. 
 
BIžanov, G. and Jonauskienė, I. 2003. Production and purification of IgY from egg 
yolk after immunization of hens with pig IgG. Bull. Vet. Inst. Pulawy 47: 403-
410.  
 
Butcher, G. D. and Miles, R. D. 2003. The avian immune system.VM74 Series. 
IFAS, University of Florida, USA. 
 
Carlander, D. 2002. Avian IgY Antibody, in vitro and in vivo. Acta Universitatis 
Upsaliensis Uppsala. pp 1-53. 
Chang, H. M.; Lu, T.C.; Chen, C.C.; Tu, Y. Y. and Hwang, J.Y. 2000. Isolation of 
immunoglobulin from egg yolk by anionic polysaccharides. J. Agric. Food 
Chem 48: 995 -999. 
Eidsen, C.S. and Kleven, S.H. 1976. A comparison of the various routes of 
Newcastle disease vaccination at one day of age. Poult.Sci. 55:1773-1787. 
 65
Gee, S. C.; Bate, I. M.; Thomas, T. M. and Rylatt, D. B. 2003. The purification of 
IgY from chicken egg yolk by preparative electrophoresis. Protein Expression 
and Purification  30: 151-155.  
Grimes, E. S. 2002. A basic laboratory manual for the small-scale     production and 
testing of I-2 Newcastle disease vaccine. FAO Regional Office for Asia and 
the Pacific (RAP) publication. 
 
Grindstaff, L. J.; Brodie III, E. D. and Ellen, D. K. 2003. Immune function across 
generations: Integrating mechanism and evolutionary process in maternal 
antibody transmission. Proc. Biol. Sci. 270:2309–2319. 
 
Haak-Frendscho, Mary. 1994. Why IgY? Chicken polyclonal antibody, an appealing 
alternative. Promega Notes Magazine 46:11 
 
Hamal, K. R.; Burgess, S. C.; Pevzner, I. Y. and Erf, G. F. 2006. Maternal antibody 
transfer from dams to their egg yolks, egg whites, and chicks in meat lines of 
chickens. Poultry Sci 85:1364–1372. 
 
Hatta, H.; Kim, M. and Yamamoto, T. 1990. A novel isolation method for hen             
egg yolk antibody, "IgY". Agric. Biol Chem. 54:2531-2535.  
 
Hofsade, M.S.; Helmboldt, C.F.; Reid,W.M. and Yoder, H.W. Jr . 1978. Diseases of 
poultry. Seventh edition. pp: 513- 532. Iowa State University Press. AMES. 
IOWA. USA.  
 
 66
Jensensius, J. C.; Anderson, I.; Han, J.; Crone, M. and Koch, C. 1981. Eggs 
conveniently packaged antibodies. Methods for purification of yolk IgG. J. 
Immunol. Methods 46: 63-68. 
 
Mahasin E. Abdel-Rahman. 1980. A study of maternal and passive immunity            
to Newcastle disease. M.Sc. thesis. University of Cambridge. Wolfson 
College. Cambridge. UK.  
 
Makvandi, M. and Fiuzi, R. 2002. Purification of Anti-HbsAg from egg yolks of 
immunized hens and its application for detection of HbsAg. Arch Iranian 
Med. 5: 91 – 93. 
 
Malik, M. W.; Ayub, N. and Qureshi, I. Z. 2006. Passive immunization using 
purified IgYs against infectious bursal disease of chickens in Pakistan. J. Vet. 
Sci. 7:43–46. 
  
Manna, C.; Manna, S. K.; Das, R.; Batabyal, K. and Roy, R. N. 2007.  Development 
of in ovo vaccine against Newcastle disease of birds. Curr. Sci. 93:1305- 1309. 
 
McMullin, P. 1985. Factors which interfere with vaccine efficacy. Proceedings of the 
1st Sta. Catarina Poultry Symposium pp10-20. 
 
Murphy, F. A.; Paul, E.; Gibbs, J.; Horzinek, M. C. and Studdert, M. J. 1999.  
Veterinary virology. Third edition. Academic Press. London. pp: 411-421. 
 
Narat, M. 2003. Production of antibodies in chickens. Food Technol. Biotechnol. 41: 
259–267. 
 
 67
Office International des Epizooties. 2001. Newcastle disease. Manual of standards 
for diagnostic tests and vaccines. 4th edn. Paris: OIE (in press). 
 
Pihlaja, M.; Siitari, H. and Alatalo, R. V. 2006. Maternal antibodies in a wild 
altricial bird: effects on offspring immunity, growth and survival. J. Anim. 
Ecol.75: 1154–1164 
 
Polson, A. 1990. Isolation of IgY from the yolks of eggs by a chloroform 
polyethylene glycol procedure. Immunol Invest. 19:253-258.  
 
Rahman, M. M.; Bari, A. S. M.; Giasuddin, M.; Islam, M.R.; Alam, J.  and Sil, G. C. 
2002. Evaluation of maternal and humoral immunity against Newcastle 
disease virus in chicken. Int. J. Poult. Sci. 1:161–163. 
 
Raj, G. D.; Latha, B.; Chandrasekhar, M. S. and Thiagarajan,V. 2004. Production, 
characterization and application of monoclonal antibodies against chicken 
IgY. Veterinarski Arhiv 74: 189-199. 
 
Roitt, I.; Brostoff, J. and Male, D. 2001. Immunology. Sixth edition. pp: 235- 243. 
Mosby. London. UK. 
 
Schade, R.; Calzado, E. G.; Sarmiento, R.; Chacana, P. A.; Porankiewicz-Asplund, J.  
and Terzolo, H. R. 2005. Chicken egg yolk antibodies (IgY-technology): A 
review of progress in production and use in research and human and 
veterinary medicine, ATLA 33: 129–154  
 
 68
Schade, R.; Staak, C.; Hendriksen, C.; Erhard, M.; Hugl, H.; Koch, G.; Larsson, A.; 
Pollmann, W.; van Regenmortel, M.; Rijke, E.; Spielmann, H.; Steinbusch, H.  
and Straughan, D. 1996. The production of avian (egg yolk) antibodies: IgY. 
ATLA 24:925–34.  
 
Seal, B. S.; King, D. J. and Sellers, H. S. 2000. The avian response to Newcastle 
disease virus. Develop.Comp.Immunol.24: 257-268. 
 
Shuaib, M.; Khan, H.; ur-Rehman, S. and Ashfaque, M. 2006.  Humoral Immune 
Response to Newcastle disease vaccine (Lastoa Strain) in broilers. Inter. J. 
Poultry Sci 5: 411-414. 
 
Snyder, D.B.; Marquardt, W.W.; Mallinson, E.T. and Russek, E. 1983. Rapid 
serological profiling by enzyme-linked immunosorbent assay. I. Measurement 
of antibody activity titre against Newcastle disease virus in a single serum 
dilution. Avian Dis. 27: 161-170 
 
Spradbrow, P.B. 1990. Epidemiology of Newcastle disease and the economics of its 
control. Proceedings of a workshop: Poultry as a tool in poverty eradication 
and promotion of gender equality. Vet. Res. Institute. Sri Lanka.Annual 
Report. 
 
Stålberg, J. and Larsson, A. 2001. Extraction of IgY from egg yolk using a novel 
aqueous two-phase system and comparison with other extraction methods. 
Upsala J Med Sci 106: 99–110. 
 
 69
Stone, H. D.; Brugh, M. and Xie, Z. 1992.  Simulation of maternal immunity by 
inoculation of immune yolk preparations into the yolk sac of 1-day-old 
chickens. Avian Dis. 36: 1048-1051. 
 
Survashe, B.D. and Desmukh, S.G. 1998. Newcastle disease prevention and control. 
Poultry international 37: 26-30. Watt Publishing Company. 
 
Szabo, Cs.; Bardos, L.; Losonczy, S. and Karchesz, K. 1998. Isolation of Antibodies 
from Chicken and Quail Eggs. Presented at INABIS '98 - 5th Internet World 
Congress on Biomedical Sciences at McMaster University, Canada, Dec 7-
16th. 
 
Tabidi M.H.; Makkawi, A.; Mahasin, E. and Ali, A.S. 2004. Comparative evaluation 
of haemagglutination inhibition test and enzyme-linked immunosorbent assay 
for detection of antibodies against Newcastle disease vaccine in broiler chicks.  
Inter.J. Poultry Sci 3: 668-670. 
 
Website 1: www.kpl.com (Technical guide for ELISA.2005). 
 
Website 2:  
C:\ Documents and settings\ Adminstration. PC144942389585\ My    
documents\references\developing an ELISA.htm. 
West, A. P., Jr.; Herr, A. B. and Bjorkman, P. J. 2004. The chicken yolk sac IgY 
receptor, a functional equivalent of the mammalian MHC-related Fc receptor, 
is a phospholipase A2 receptor homolog. Immunity 20:601–610.  
 70
Yoshinori, M. and Kovacs-Nolan, J. 2002 Chicken egg yolk antibodies as 
therapeutics in enteric infectious disease: A Review, J. Med. Food 5: 159-169. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 71
APPENDIX 1 
Table 1: Maternal specific NDV antibody titer in individual egg measured by 
standardized indirect ELISA (In- house ELISA) 
 
Sample 
number 
Absorbance 
(OD) 
result titer Log 2 
1  0.987 pos 12800 13.643 
2 0.796 pos 3200 11.643 
3 1.109 pos 12800 13.643 
4 0.928 pos 6400 12.643 
5 1.004 pos 12800 13.643 
6 1.392 pos 12800 13.643 
7 0.967 pos 12800 13.643 
8 0.865 pos 6400 12.643 
9 0.642 pos 800 9.643 
10 0.561 pos 400 8.643 
11 0.774 pos 1600 10.643 
12 0.672 pos 800 9.643 
13 0.769 pos 3200 11.643 
14 0.577 pos 400 8.643 
15 0.901 pos 6400 12.643 
16 0.695 pos 800 9.643 
17 0.742 pos 1600 10.643 
18 0.794 pos 3200 11.643 
19 0.568 pos 400 8.643 
20 0.701 pos 800 9.643 
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21 0.717 pos 1600 10.643 
22 0.765 pos 1600 10.643 
23 0.849 pos 3200 11.643 
24 0.779 pos 3200 11.643 
25 0.866 pos 6400 12.643 
26 0.903 pos 6400 12.643 
27 0.706 pos 1600 10.643 
28 0.878 pos 6400 12.643 
29 0.906 pos 6400 12.643 
30 0.887 pos 6400 12.643 
31 0.864 pos 6400 12.643 
32 0.971 pos 12800 13.643 
33 0.898 pos 6400 12.643 
34 0.911 pos 6400 12.643 
35 0.916 pos 6400 12.643 
36 1.002 pos 6400 12.643 
37 0.612 pos 400 8.643 
38 0.964 pos 12800 13.643 
39 0.853 pos 6400 12.643 
40 0.866 pos 6400 12.643 
41 0.782 pos 3200 11.643 
42 0.793 pos 3200 11.643 
43 0.844 pos 3200 11.643 
44 0.762 pos 1600 10.643 
45 0.659 pos 800 9.643 
46 0.760 pos 1600 10.643 
 73
47 0.486 pos 400 8.643 
48 0.495 pos 400 8.643 
49 0.761 pos 1600 10.643 
50 0.802 pos 3200 11.643 
51 0.531 pos 400 8.643 
52 0.951 pos 12800 13.643 
53 0.853 pos 6400 12.643 
54 0.456 pos 400 8.643 
55 0.908 pos 6400 12.643 
56 1.063 pos 12800 13.643 
57 0.987 pos 12800 13.643 
58 0.901 pos 6400 12.643 
59 0.644 pos 800 9.643 
60 0.612 pos 400 8.643 
61 0.581 pos 400 8.643 
62 0.750 pos 1600 10.643 
63 0.803 pos 3200 11.643 
64 0.747 pos 1600 10.643 
65 0.898 pos 6400 12.643 
66 0.976 pos 12800 13.643 
67 0.889 pos 6400 12.643 
68 0.869 pos 6400 12.643 
69 0.811 pos 3200 11.643 
70 0.979 pos 12800 13.643 
71 0.642 pos 800 9.643 
72  0.967 pos 12800 13.643 
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73  1.134 pos 12800 13.643 
74 0.777 pos 1600 10.643 
75 0.858 pos 6400 12.643 
76 0.894 pos 6400 12.643 
77 1.065 pos 12800 13.643 
78 0.807 pos 3200 11.643 
79 1.177 pos 12800 13.643 
80 0.772 pos 1600 10.643 
81 0.533 pos 400 8.643 
82 0.668 pos 400 8.643 
83 1.208 pos 12800 13.643 
84 0.807 pos 3200 11.643 
85 0.585 pos 400 8.643 
86 0.720 pos 1600 10.643 
87 0.878 pos 6400 12.643 
88 0.720 pos 1600 10.643 
89 0.835 pos 3200 11.643 
90 0.707 pos 1600 10.643 
91 0.911 pos 6400 12.643 
92 0.879 pos 6400 12.643 
93 0.789 pos 3200 11.643 
94 1.117 pos 12800 13.643 
95 0.818 pos 3200 11.643 
96 0.725 pos 1600 10.643 
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APPENDIX 2 
Table 2: Maternal specific NDV antibody titer in individual egg measured by 
commercial NDV ELISA test kits 
  
Sample 
number 
Absorbance 
(OD) 
S/P result titer Log 2 
6 0.990 6.779 Pos 18.449 14.171 
7 0.505 3.314 Pos 8456 13.046 
8 0.534 3.521 Pos 9034 13.141 
9 0.431 2.786 Pos 6999 12.773 
10 0.501 3.286 pos 8379 13.033 
11 0.517 3.400 pos 8696 13.086 
12 0.155 0.814 pos 1831 10.838 
13 0.231 1.357 pos 3195 11.642 
14 0.585 3.886 pos 10059 13.296 
15 0.590 3.921 pos 10158 13.310 
16 0.824 5.593 pos 14960 13.869 
17 0.722 4.864 pos 12848 13.649 
18 0.801 5.429 pos 14483 13.822 
19 0.865 5.885 pos 15816 13.949 
20 0.453 2.943 pos 7430 12.895 
21 0.636 4.250 pos 11090 13.437 
22 0.619 4.129 pos 10747 13.392 
23 0.281 1.714 pos 4122 12.009 
24 0.274 1.664 pos 3991 11.963 
25 0.403 2.586 pos 6453 12.656 
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26 0.478 3.121 pos 7921 12.951 
27  0.464 3.021 pos 7645 12.900 
28 0.489 3.200 pos 8140 12.991 
29 0.536 3.536 pos 9076 13.148 
30 0.408 2.621 pos 6548 12.677 
31 0.481 3.143 pos 7982 12.963 
32 0.445 2.886 pos 7273 12.828 
33 0.441 2.857 pos 7194 12.813 
34 0.412 2.650 pos 6627 12.964 
35 0.354 2.236 pos 5507 12.427 
36 0.286 1.750 pos 4216 12.042 
37 0.417 2.686 pos 6726 12.716 
38 0.862 5.864 pos 15752 13.943 
39 0.633 4.229 pos 11031 13.429 
40 0.519 3.414 pos 8735 13.093 
41 0.501 3.286 pos 8379 13.033 
42 0.522 3.436 pos 8796 13.103 
43 0.689 4.629 pos 12173 13.571 
44 0.424 2.736 pos 6862 12.744 
45 0.646 4.321 pos 11292 13.463 
46 0.462 3.007 pos     7606 12.893 
47 0.488 3.193 pos 8120  12.987 
48 0.528 3.479 pos 8916 13.122 
49 0.340 2.136 pos 5239 12.355 
50 0.856 5.821 pos 15626 13.932 
51 0.292 1.793 pos 4329 12.080 
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52 0.677 4.543 pos 11926 13.542 
53 0.363 2.300 pos 5679 12.471 
54 0.674 4.521 pos 11863 13.534 
55 0.354 2.236 pos 5507 12.427 
56 0.463 3.014 pos 7625 12.897 
57 0.477 3.114 pos 7902 12.948 
58 0.497 3.257 pos 8298 13.019 
59 0.265 1.600 pos 3824 11.901 
60 0.350 2.207 pos 5429 12.406 
61 0.301 1.857 pos 4498 12.135 
62 0.524 3.450 pos 8835 13.109 
63 0.455 2.957 pos 7468 12.867 
64 0.398 2.550 pos 6355 12.634 
65 0.441 2.857 pos 7194 12.813 
66 0.503 3.300      pos 8417 13.039 
67 0.269 1.629 pos 3899 11.929 
68 0.498 3.264 pos 8317 13.022 
69 0.322 2.007 pos 4895 12.257 
70 0.432 2.786 pos 6999 12.773 
71 0.506 3.321 pos 8476 13.049 
72 0.519 3.414 pos 8735 13.093 
73 0.445 2.886 pos 7273 12.828 
74 0.460 2.993 pos 7568 12.886 
75 0.450 2.921 pos 7369 12.847 
76 0.538 3.550 pos 9115 13.154 
77 0.507 3.329 pos 8498 13.053 
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78 0.216 1.250 pos 2922 11.513 
79 0.370 2.350 pos 5814 12.505 
80 0.320 1.993 pos 4858 12.246 
81 0.458 2.979 pos 7529 12.878 
82 0.302 1.864 pos 4516 12.141 
83 0.364 2.307      pos 5698 12.476 
84 0.912 1.271 pos 2975 11.539 
85 0.262 1.579 pos 3769 11.880 
86 0.358 2.264 pos 5582 12.447 
87 0.391 2.500 pos 6219 12.602 
88 0.339 2.129 pos 5220 12.350 
89 0.292 1.793 pos 4329 12.080 
90 0.383 2.443 pos 6065 12.566 
91 0.342 2.150 pos 5277 12.366 
92 0.298 1.836 pos 4442 12.117 
93 0.366 2.321 pos 5736 12.486 
94 0.257 1.543 pos 3676 11.844 
95 0.322 2.007 pos 4895 12.257 
4 0.371 2.357 pos 5833 12.510 
5 0.666 4.464 pos 11700 13.514 
 
 
 
 
 
 
 
